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Abstract
Streptococcus pyogenes is a human-specific pathogen that is responsible for serious
morbidity and mortality worldwide despite being susceptible to common antibiotics.
Furthermore, there is currently no licensed vaccine available against this organism.
Previous research from our laboratory implicated a critical role for superantigens in a
transgenic mouse model of acute nasopharyngeal infection by S. pyogenes. Herein, we are
able to detect superantigen production in vivo and establish that anti-superantigen
antibodies generated by either passive immunization or active vaccination with a major
histocompatibility complex II-binding interface superantigen toxoid reduces S. pyogenes
nasopharyngeal burden. We were also able to demonstrate that this organism requires
responsive Vβ-specific T cells in order to efficiently infect the upper respiratory tract.
These experiments remarkably reveal that S. pyogenes manipulates T cells to promote
infection and also supports targeting superantigens as vaccine candidates to prevent
nasopharyngeal carrier and subsequent disease caused by this globally important pathogen.
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Introduction
This thesis introduction will broadly outline what is known about S. pyogenes. It will first
examine disease manifestations from a clinical perspective followed by descriptions of the
best-studied virulence factors. Animal models of infection will then be discussed which
will be concluded by current vaccine approaches against this organism. Emphasis should
be paid to information regarding streptococcal SAgs and their role in infectious disease as
well as limitations to current vaccine approaches.
Streptococcus pyogenes
Streptococcus pyogenes (or Lancefield’s group A streptococci; GAS) is a Gram-positive,
non-motile, non-sporeforming, aerotolerant anaerobic bacterium, generally round or ovoid
and 0.5 to 1 µm in diameter. It grows in pairs or chains of varying length and when grown
with blood, it exhibits β-hemolysis or complete lysis of red blood cells. The only known
natural reservoir for this organism are humans, and it has been shown to colonize the skin,
throat, vagina and rectum [1]. S. pyogenes is an important human pathogen capable of
causing severe diseases such as necrotizing fasciitis and streptococcal toxic shock
syndrome as well as mild illnesses such as pharyngitis or impetigo [2]. Individuals can also
be asymptomatic carriers of the bacterium [3]. There are numerous post-infection, nonsuppurative sequelae caused by this organism including glomerulonephritis, acute
rheumatic fever (ARF) and rheumatic heart disease (RHD) [2]. S. pyogenes bacteria remain
susceptible to β-lactam antibiotics and there is currently no human-approved vaccine
available.
Invasive streptococcal disease
Invasive infections are defined as the isolation of the infecting organism from a normally
sterile site. In regards to S. pyogenes, this includes invasion into deep tissues (such as the
fascia [necrotizing fasciitis; NF] or the muscle [myositis]), bacteremia and streptococcal
toxic shock syndrome (STSS). In 2005, it was documented that there were over 660,000
new cases of invasive infections each year caused by S. pyogenes resulting in over 160,000
deaths [4]. These were overwhelmingly in developing nations and thus it is thought that
this number was an underrepresentation. Data from recent decades suggest that the
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incidence and severity of invasive diseases has increased and this trend seems to be
continuing [4–7].
NF is an infection of the underlying human subcutaneous tissue and fascia that results in
inflammation and necrosis. It can be caused by numerous other organisms, but due to
commonality and severity of tissue trauma, S. pyogenes has been termed the ‘flesh-eating
bacteria’. Infection starts at an often trivial or sometimes benign site with minimal
inflammation, but quickly worsens within the next 24-72 hours. A hallmark of NF is
disproportionate pain to size of injury [8,9], which can help differentiate it from less severe
tissue infections (impetigo, cellulitis), although differentiation is still difficult. Upon
worsening, fever and severe pain become consistent, skin becomes ‘dusky’ and purplish,
with edema occurring (filled with yellow or hemorrhagic fluid). These are all signs of the
underlying necrosis, which spreads rapidly, and sloughing of the skin can be observed.
Treatment consists of removal of infected tissue (debridement and pus drainage),
antibiotics to treat the infection (β-lactams [penicillin] and/or protein synthesis inhibitors
[clindamycin]), and aggressive supportive care (hemodynamic stabilization, nutritional
supplementation and analgesic therapy) [2,10,11]. Mortality rates associated with NF are
generally high, with case fatality rates reaching up to 50% in some settings [6,12–14].
STSS typically involves an invasive streptococcal infection associated with hypotension,
shock and organ failure, and the clinical definition can be found in Table 1. Early
symptoms may include pharyngitis, muscle pain, swollen lymph nodes and/or fever,
followed by a sudden onset of vomiting, diarrhea, rash and hypotension. If symptoms
persist, they may eventually result in multiple organ failure and potentially death. Unlike
staphylococcal toxic shock syndrome (TSS), most STSS patients are bacteremic as well
[15,16]. Mortality rates increase over NF and are generally between 30 and 70% [17–19].
Although the etiology of STSS is multifactorial, secreted toxins are thought to be
significant contributors to the pathology [20]. Treatment of STSS is similar to NF and there
is also evidence that administration of intravenous immunoglobulins (IVIG) can help
reduce mortality by toxin neutralization [21,22].
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Superficial and locally invasive infections
S. pyogenes is known to cause numerous superficial skin and soft tissue infections. The
most common are pharyngitis (commonly known as ‘strep throat’) and pyoderma, of which
there were over 600 million and 100 million incidence cases per year, respectively, as of
2005 [4]. It is possible that these infections may seed the severe and invasive diseases
previously outlined, or result in post-infection sequelae as discussed below. While
pharyngitis is widespread around the world, skin infections are much more common in
resource poor settings due to inadequate hygiene and living conditions.
‘Strep throat’ is the most common manifestation of S. pyogenes infection and is also the
most common cause of bacterial pharyngitis. It constitutes between 20 to 40% of all
pharyngitis cases in children and between 5 to 15% in adults [23,24]. Symptoms occur
abruptly and may include: sore throat (pain described as severe), moderate fever (39°C to
40.5°C), malaise, chills, headache, neck stiffness, and gastrointestinal symptoms (nausea,
vomiting, abdominal pain). Examination of the throat reveals erythema and edema with
purulent exudate forming on the tonsils. Cervical lymph nodes may become enlarged and
tender. It is possible that fine erythematous papules become apparent on the trunk and
spread towards the extremities with a sandpapery feel (scarlatiniform rash) and enlarged
papillae may present on the tongue. These characteristics advance the diagnosis to ‘scarlet
fever’, a similar, toxin-mediated illness associated with S. pyogenes [24]. These illnesses
are self-limiting, and last around 8 to 10 days. However, due to the numerous potential
complications associated with untreated S. pyogenes infections, antibiotic treatment is
common which generally sees signs and symptoms subside within 24 to 48 hours.
S. pyogenes is capable of causing numerous non-life threatening skin and soft tissue
infections and classification is dependent upon which layer of the skin is involved.
Infection of the superficial keratin layer (impetigo), the epidermis (erysipelas) and the
subcutaneous tissue (cellulitis) are all possible. Impetigo manifests as a papule with a
surrounding area of erythema. Pustules arise, breakdown and form a thick crust, heal
slowly, and may leave depigmented areas. Since other common skin dwelling bacteria such
as Staphylococcus aureus more commonly cause impetigo, and are penicillin resistant, it
may be difficult to discern the causative agent and treat appropriately. An FDA approved
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Table 1. Streptococcal toxic shock syndrome case definition
I.
Isolation of S. pyogenes from:
Definite:
Probable:
Normally sterile site
Nonsterile site
and
II.
Hypotension
and
III.
Two or more of the following:
Renal impairment
Coagulopathy
Liver involvement
General erythematous macular rash
Tissue necrosis
Respiratory distress
From The Working Group on Severe Streptococcal Infections [19]
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antibacterial, retapamulin, is also approved for treatment of methicillin-susceptible S.
aureus and S. pyogenes impetigo [25].
Erysipelas is an infection of the dermis, but has lymphatic involvement. It is distinguishable
by three features: the lesions are raised above the surrounding skin; a clear line of
demarcation between involved and uninvolved skin; and a salmon-red colouring. Unlike
impetigo, erysipelas is almost always caused by S. pyogenes. Upon infection, lesions begin
to swell, become erythematic and become raised. If infection occurs on the face, it is
common for eyes to become swollen shut. Chills and fever are also commonly associated.
It is rare for infections to spread deeper and because a high proportion of cases are caused
by S. pyogenes, penicillin is commonly used to treat these infections.
Cellulitis occurs mainly from infections of burns, wounds, or surgical incisions. Symptoms
include local pain, tenderness, swelling and erythema. There may be rapid spreading into
the skin, and can contrast with erysipelas because lesions are not raised and demarcation
between involved and uninvolved skin is indistinct. Fever, chills and malaise may be
present, and bacterial spreading to lymphatics (lymphangitis), blood (bacteremia) or both
is possible. Much like impetigo, it is hard to differentiate between cellulitis caused by S.
pyogenes and S. aureus. Semi-synthetic penicillinase-resistant penicillin, cephalosporin,
clindamycin, linezolid or vancomycin may be used to treat cellulitis, depending on the
circumstances.
Asymptomatic Carriage
Asymptomatic carriage is described as the presence of bacteria in the absence of signs or
symptoms of infection. S. pyogenes is known to inhabit the human nasopharynx, genital
mucosa, rectum, and skin in both pathogenic and benign instances. The majority of studies
have studied asymptomatic colonization of the upper respiratory tract, and rates are
typically around 12% for school aged children (5 to 18 years old) and much lower for adults
and younger children [23,26]. Carriers do not seem to be at a higher rate of acquired
immune disorders, and since they do not present with symptoms (coughing, coryza), they
are found to be ineffective as transmitters. It is difficult to determine if carriers are more
likely to have invasive infections because it is usually not possible to determine if a patient
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was a carrier prior to an invasive infection. However, it has been shown that those suffering
from invasive infections have close contacts that often contain S. pyogenes in the pharynx
[27,28]. The asymptomatic carriage state of S. pyogenes remains an enigma and will
probably remain so until more conclusive associations can be found.
Post-infection sequelae
In 2005, it was estimated that S. pyogenes was associated with over 500,000 deaths each
year due to severe and invasive diseases. From a morbidity and mortality standpoint, there
were over 15.6 million cases of streptococcal post-infection sequelae per year and these
resulted in the highest death rates (over 233,000 deaths per year) of all GAS-associated
illnesses [4]. Streptococcal post-infection sequelae arise from molecular mimicry, whereby
the host’s immune system not only generates a response against the invading organism, but
also against self, due to bacterial factors that contain cross-reactive epitopes with human
molecules. The two main molecules implicated in these types of diseases include the
surface M protein and the group A carbohydrate (specifically, the dominant epitope of Nacetyl-β-D-glucosamine) [29,30].
Acute rheumatic fever (ARF) is a delayed inflammatory illness that generally appears two
weeks after S. pyogenes pharyngitis. ARF is diagnosed based on modified Jones Criteria
(Table 2) in which an individual with evidence of preceding S. pyogenes infection (positive
throat culture, positive rapid streptococcal antigen test or elevated anti-streptococcal
antibodies) has a combination of two major manifestations, one major and two minor
manifestations or three minor manifestations (depending on whether it was an initial or
recurring ARF episode). Major criteria indicate the site of inflammation (heart, joints,
brain, skin and/or subcutaneous tissue) and the minor criteria demonstrate clinical or
laboratory findings (fever, joint pain [arthralgia], elevated acute phase reactants [increased
erythrocyte sedimentation rate and C-reactive protein] and/or prolonged PR interval on an
electrocardiogram). There are more than 470,000 cases of ARF each year and the majority
are in children between the ages of 5 and 14 [4]. Most cases present in poor socioeconomic
and developing nations and because of that, data are thought to be underrepresented. More
specifically, rates are highest among Pacific populations, specifically those of aboriginal
decent [31]. Repeated streptococcal infections and exacerbation of ARF can lead to
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Table 2. Modified Jones criteria for diagnosis of acute rheumatic fever
For all patient populations with evidence of preceding GAS infection
Initial ARF
2 major manifestations OR
1 major plus 2 minor manifestations
Recurrent ARF

Major Criteria
Low-risk populations*
 Carditisǂ
 Arthritis
Polyarthritis only

2 major manifestations OR
1 major and 2 minor manifestations OR
3 minor manifestations
Moderate- and high-risk populations
 Carditisǂ
 Arthritis
Mono- or polyarthritis
Polyarthralgia
 Chorea
 Erythema marginatum
 Subcutaneous nodules

 Chorea
 Erythema marginatum
 Subcutaneous nodules
Minor Criteria
Low-risk populations*
Moderate- and high-risk populations
 Polyarthralgia†
 Monoarthralgia†
 Fever (≥38.5°C)
 Fever (≥38°C)
 ESR ≥60 mm in the first
 ESR ≥30 mm/h and/or CRP ≥3 mg/dL
hour and/or CRP ≥3 mg/dL
 Prolonged PR interval‡
 Prolonged PR interval‡
Adapted from Gewitz et. al. [32]
GAS, group A Streptococcus; ARF, acute rheumatic fever; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein
*Low-risk population are those with incidence ≤2 per 100,000 school-aged children with
ARF or all-age rheumatic heart disease prevalence of ≤1 per 1000 population per year
ǂClinical (based on auscultation of typical murmurs) or subclinical (based on
echocardiography)
†Joint manifestations can only be considered in either the major or the minor categories
but not both in the same patient
‡Can only be used if carditis is not a major criterion

9

sustained damage of the heart. This clinical manifestation is known as rheumatic heart
disease (RHD) and can involve any heart valve, but damage to the mitral and aortic valves
are most common [4]. Determinants of progression are poorly understood and initial
clinical presentation can range from asymptomatic valvular dysfunction to heart failure.
The severity of the initial ARF case and recurrent S. pyogenes infections are known to be
important factors in the progression of this disease [33] which can lead to other
complications including infective endocarditis, atrial fibrillation and thrombolembolic
stroke [34]. RHD is the number one cause of mortality associated with S. pyogenes
infections. The Global Burden of Disease study recently indicated that there are 33 million
prevalent cases of this disease, causing more than 275,000 deaths each year and more than
9 million Disability-Adjusted Life Years (DALYs) lost [30,35–37].
Treatment for ARF is supportive, supplemented with antibiotics to treat infections and antiinflammatory medication. Secondary prophylaxis with antibiotics reduces the risk of RHD
in patients with ARF and can also slow the progression and severity of disease in patients
with established RHD [38,39]. In developed countries, surgical intervention of individuals
with progressed RHD is also possible.
Post-streptococcal glomerulonephritis (PSGN) is the most common cause of acute
nephritis in children worldwide but can also occur in adults. It may typically occur after
either pharyngitis (1 to 3 weeks) or impetigo (3 to 6 weeks) [40]. PSGN is thought to be
due to inflammation as a result of deposition of complement component C3 and IgG in the
kidneys. As of 2005, there were over 470,000 cases each year worldwide [4], mostly
resulting from epidemics of impetigo in tropical countries [34]. Most common
presentations of PSGN are haematuria and oedema with hypertension in around 60% of
cases [41]. Full blown renal failure is rare, and death is seen in less than 1% of cases [4].
Usually, symptoms subside within 6-8 weeks without any treatment.
Group A Streptococcus Genome
Based on 19 completed genomes, the 'core' of S. pyogenes genome is composed of a single,
~1.8 Mbp circular chromosome with a G+C content of 38.5 ± 0.1%. There are 1,826 ± 92
protein-coding regions, 5 or 6 rRNA operons, and 57 to 67 tRNA genes [42]. A major
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source of genetic variability between strains is due to mobile (or putatively mobile) genetic
elements including integrative conjugative elements (ICEs) as well as phage and phagelike insertional sequences that generally harbor numerous virulence and adherence factors
[43,44]. Many 'hallmark' virulence factors of S. pyogenes can be found on the ‘core’
genome including: M protein, the cysteine protease SpeB, the genes responsible for the
production of the hyaluronic acid capsule and hemolysins, among numerous others. Genes
on mobile genetic elements include DNases, antibiotic resistances and many of the
streptococcal SAgs.
Streptococcal virulence factors
1.7.1

M Protein

The M protein is one of the best-studied surface molecules on Gram-positive organisms
and is a major surface determinant present on S. pyogenes. The M protein plays a major
role in virulence due to its ability to bind to numerous host factors (albumin, fibrinogen,
factor H, IgG), preventing non-antibody mediated phagocytosis by PMN cells and
mediating adherence to host tissues [29,45].
The M protein is a multi-domain, alpha-helical coiled-coiled dimer that is anchored to the
bacterial cell wall at the C-terminus through an LPXTG motif [29,46,47]. The
hypervariable N-terminus of the M protein differs amongst strains and a region of about 50
amino acids generates enough variability to aid in the classification of S. pyogenes.
Serospecificity to this portion originally helped classify streptococci (known as M types);
however, with the development of sequencing technology, a genetic classification system
has been generated based on the nucleic acid sequence of this region (emm type) [48]. The
genetic variability in this region has led to the discovery of over 200 emm types [49]. Based
on the M6 protein – the ‘prototype’ M protein – the central region is made up of several,
multiple repeat regions. Typically, the M protein is comprised of four repeat regions –
designated A-D from the N- to the C-terminus – which make up the central helical rod of
the M molecule. The upper A and B repeat regions are more variable between emm types
with higher conservation in the C and D repeat regions. The C-terminus is composed of a
mixture of positively and negatively charged amino acids, which are conserved amongst
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many surface proteins. Just N-terminal of this is a hydrophobic core of around 15-22 amino
acids (sufficient to span the cytoplasmic membrane) followed by the LPXTG consensus
sequence. This sequence is recognized and cleaved by streptococcal sortase and
incorporated into the cell wall.
Other M proteins structures exist and they generally contain some, but not all of the
aforementioned features. Thus, emm-typing is not as informative in regards to sequence,
predicted structure or functional domains. A closely related typing method called emm
pattern-typing distinguishes chromosomal architecture by taking into account the presence
and arrangement of emm genes in the chromosome [50] with evidence that emm types
correlate with emm patterns [51]. The emm patterns have been broken down into A-C
pattern (e.g. M6), D pattern (e.g. M80) which lack the A repeats in the central helical
domain, and the E pattern (e.g. M77) which lacks both A and B repeats. Although the best
studied pattern is A-C, they account for approximately 20 percent of isolated organisms
while other patterns account for approximately 75% [52].
Importantly, there have been associations of certain M types with disease phenotypes such
as pharyngitis, impetigo and post-infection autoimmune sequelae [53–57]. This disease
association with typing also stems to emm [13,14,58] and emm pattern-typing whereby the
majority of pharyngitis isolates were found to associate with pattern A-C and impetigo
isolates belonging to pattern D, whereas Pattern E was considered to be a ‘generalist’ group
[44,52,59,60]. These data indicate the complexity of S. pyogenes classification, but also
their importance in regards to disease association and potential implication in vaccine
development.
1.7.2

Capsule

The capsule of S. pyogenes is composed of hyaluronic acid, a linear polymer of Nacetylglucosamine and glucuronic acid. It is present on most, but not all clinical isolates in
varying amounts and when present it gives the organism a mucoid colony morphology.
The composition of the capsule is identical to hyaluronic acid found within the human host,
which suggests that it may play a role in molecular mimicry and immune evasion. The
capsule has been linked to virulence and it has been shown to increase resistance to
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phagocytosis and aid in adherence to the pharynx by binding CD44 [61–64]. This is further
demonstrated by the fact that hyper-encapsulated strains are frequently recovered from
patients with invasive GAS infections [65]. The capsule is synthesized by the product of
three genes that are found in the same operon and transcribed by the same promoter [66,67].
The hasA, hasB and hasC genes encode the hyaluronate synthase, UDP-glucose
dehydrogenase and UDP-glucose pyrophosphorylase, respectively [68–71]. Interestingly,
only hasA and hasB appears to be required for capsule expression [72]. These genes are
regulated by the covRS (control of virulence; originally named capsule synthesis regulator
[csr]) two component system [73]. A second regulator, rocA (regulator of Cov) was also
shown to activate transcription of the repressor covR and thus has a negative impact on
capsule production [74].
1.7.3

Streptococcal pyrogenic exotoxin B protease

Streptococcal pyrogenic exotoxin B (SpeB) is a secreted cysteine proteinase that was
originally thought to have pyrogenic and mitogenic activity [75], but this was later shown
to be due to contamination. SpeB is produced in response to starvation during late log to
early stationary phase in culture, as a 40 kDa inactive zymogen [76]. It then undergoes
autocatalytic cleavage and conversion to a 28 kDa active enzyme [77]. Its proteinase
activity is mediated by a cysteine at position 192 whereby upon mutation, the protein loses
this function [78]. SpeB is known to cleave a number of host (vitronectin [79], fibronectin
[79], IL-1β precursor [80], immunoglobulins [Ig] [81], complement 3 [82], chemokines
CXCL 1-7, 10-14, 16 [83]) and bacterial (M protein [84], streptococcal mitogenic exotoxin
Z [SmeZ] [85], streptokinase [86]) factors [87]. This overwhelming influence on the host
and bacterium would suggest that this protease plays a key role in virulence. Essentially all
clinical isolate strains encode speB [88] and in one study, over 84% of S. pyogenes strains
demonstrated ‘wild-type’ SpeB activity (as assessed by casein hydrolysis assay) when
compared to a reference strain [89]. However, the role of SpeB in pathogenesis is still not
well defined. One study examining the invasive M1T1 isolate found that administration of
a SpeB+ phenotypic strain into a subcutaneous murine chamber model resulted in a phaseshift to SpeB-. Supernatants from SpeB- bacteria were also more immune stimulating than
the parental SpeB+ strain [90]. But as mentioned above, the ability of SpeB to degrade
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numerous host factors could play a beneficial role during infection. Expression of SpeB is
highly regulated by the two-component system CovRS in which non-phosphorylated CovR
represses the expression of speB [2,91]. It is likely that SpeB plays numerous roles during
different types of infections and further research will be required to fully understand this
cysteine protease.
1.7.4

Streptococcus pyogenes cell envelope protease

The S. pyogenes cell envelope protease (SpyCEP; ScpC) is capable of cleaving all human
CXC chemokines that contain the ELR motif (including the neutrophil chemotractant IL8) [92–94]. SpyCEP is produced as a 170 kDa zymogen which undergoes autocatalytic
cleavage to form two peptides which noncovalently link to form the active protease [92,95].
It can exist as either a secreted or cell-associated form and is produced throughout
exponential growth [92,96]. Transcription is thought to be regulated by both the signaling
peptide SilCR and the CovRS two-component regulatory system [97,98]. In vitro and in
vivo models examining SpyCEP as a virulence factor are not completely conclusive, but it
has been shown to mediate bacterial spread and impede clearance. Interestingly, expression
of this molecule by Lactococcus lactis did produce hallmarks of streptococcal systemic
infections [94,98–100]. To support the role of SpyCEP as a virulence factor, along with S.
pyogenes, a number of other pathogenic streptococci also produce homologues of this
protease [101].
1.7.5

Streptococcal C5a peptidase

The S. pyogenes C5a peptidase (ScpA) is a 130 kDa proteolytic enzyme that cleaves the
complement-driven chemotaxin C5a at the PMN-binding site [102,103] which thus inhibits
recruitment of phagocytic cells to the site of infection [103,104]. The scpA gene is
controlled by the mga regulator [105,106] and the protein is bound to the bacterial cell
surface by sortase A [107,108]. The importance of this molecule in bacterial fitness is
supported by C5a peptidase homologues being found in Group B Streptococcus, which are
thought to have arisen by horizontal gene transfer [109]. In mouse models of infection,
bacterial strains without C5a peptidase were cleared more efficiently from an air sac model
[104] and a nasopharyngeal infection model [110] compared to the wild-type strains.
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1.7.6

Streptococcal inhibitor of complement-mediated lysis

The streptococcal inhibitor of complement-mediated lysis (SIC) is a 31 kDa extracellular
protein with multiple functions. SIC inhibits the formation of the membrane attack complex
[111,112], inhibits the activity of antimicrobial peptide LL-37, and also inhibits the
function of lysozyme, secretory leukocyte proteinase inhibitor and defensins [113–115],
the chemokine MIG (CXCL9) [116] and interferes with the activation of the contact system
of the innate immune response [117]. Evidence also exists that SIC may play a role in
adhesion and colonization [118,119]. Interestingly, there is high variation in sic between
GAS strains [114,120,121] which is thought to have arisen in response to host immune
pressure during epidemics to enhance survival in vivo [122].
1.7.7

Hemolysins

There are two major hemolysins secreted by S. pyogenes, Streptolysins O (SLO) and S
(SLS). Both of these molecules have varying effects on a number of cell types.
SLO is a 69 kDa cholesterol-dependent, thiol-activated, pore-forming cytotoxin that is also
oxygen-labile. Pore formation in a host cell membrane occurs with binding of monomers
in a cholesterol-dependent manner, in which there may also be glycan involvement. This
is followed by oligomerization resulting in completion of the intact pore and can lead to
apoptosis of the cell by disruption of membrane integrity [123–126]. SLO and another GAS
product, NAD-glycohydrolase (S. pyogenes NAD-glycohydrolase [SPN]; encoded by the
nga gene) are co-transcribed and it has been shown that SLO is required for the
translocation of this molecule into host cells via a 70-residue N-terminal region on SLO.
Inside the cell they act synergistically to trigger cell cytotoxicity [127]. Interestingly,
cholesterol and pore formation are not required for this translocation [128–130]. SLO is
thought to potentially play a role in barrier penetration, whereby SLO-mediated epithelial
lysis allows toxin and bacteria to gain access to sub epithelial sites [131,132]. SLO has
been shown to be an important virulence factor for GAS, as mutants lacking this molecule
were less virulent in murine models [126,133,134]. The presence of SLO expression in
human infections is supported by the fact that SLO is highly immunogenic and anti-SLO
antibody titres are used as evidence of GAS infection [135,136].
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Streptolysin S (SLS) was first differentiated from SLO in 1938 by E. W. Todd, who also
determined it was oxygen-stable (unlike SLO) and highly soluble in serum [137]. Later
research would go on to show that a nine-gene operon (sagA-I) is responsible for the
production of the 53 amino acid precursor (sagA), post-translational modification enzymes
(sagB-D), immunity gene (sagE) and exporter (sagG-I) [138,139]. Each of these genes is
required for expression of functional SLS, which is a 2.7 kDa, heterocyclic compound
responsible for the β-hemolytic phenotype of GAS [140,141]. SLS cytolytic activity
requires association with the bacterial cell surface or a carrier molecule [142,143] and is
broad, including erythrocytes [137], leukocytes [144], platelets [145] and subcellular
organelles [146,147]. SLS is related to class I bacteriocins [138] and cytolytic activity is
thought to be similar to complement-mediated lysis, in which pore formation leads to
osmotic lysis [148]. More recent research indicates a possible role for SLS in host cell
signaling pathways at sub-lytic concentrations [149]. SLS is non-immunogenic, which is
thought to be due to its post-translational modification and toxic effect on white blood cells
[139]; however, neutralizing antibodies can be raised against synthetic peptide variants
[150]. SLS was determined to be important in mouse models of GAS infection [151,152];
however, GAS strains with mutations in the SLS biosynthetic operon (non-hemolytic) have
been shown to cause soft tissue infections, pharyngitis and otitis media [153,154].
1.7.8

Streptokinase

Streptokinase (Ska; encoded by the ska gene) is a 46 kDa, multi-domain protein that nonenzymatically converts the inactive zymogen plasminogen (Plg) to its proteolytically active
form, plasmin (Plm) [155–157]. Conversion is thought to occur in a two-cycle pathway:
(1) Trigger cycle - binding of Ska to Plg induces a conformational change in Plg resulting
in the formation of an active site in the complex, where cleavage of Plg to Plm occurs. (2)
Bullet cycle – Ska-Plm complex can bind a second Plg molecule which is quickly
converted to Plm. One of the Plm is removed and another Plg can be bound and the cycle
continues [158–160]. Variants of this protein are secreted by Group A, C and G
streptococci which have functional differences and can be subdivided into two categories
[161–163]. The role of Ska during infection is thought to be that activation of Plg to Plm
increases dissemination by degradation of host extracellular matrix proteins both directly
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and indirectly [2,29]. Ska is regulated by the two-component systems CovRS and FasBCA
[91,164–167] and can be cleaved by SpeB [86]. Transgenic mice expressing human
plasminogen had higher mortality when infected with GAS and susceptibility was
dependent on Ska expression [168]. A novel inhibitor that reduces Ska gene expression
also proved protective in this model, implicating a role for Ska in GAS pathogenesis [169].
1.7.9

Superantigens
General Introduction

The term ‘superantigen’ was first coined by Philippa Marrack and John Kappler in 1989
due to the strong and specific reactivity of this family of toxins with T cells bearing specific
T cell receptor (TCR) variable-beta (Vβ) chains with little input from other variable
elements [170]. These toxins, however, were previously known to have mitogenic effects
towards lymphocytes [171] and were actually discovered in the 1920s by George and
Gladys Dick as the causative agent in scarlet fever [172]. Following these landmark papers,
there have been numerous advancements in the field of SAg research which have aided in
our understanding of these toxins. These findings include the diverse number of SAgs
encoded by numerous organisms, their mode of action and the role they play in many
diseases.
Superantigen Diversity
Superantigenic molecules can be found in both gram-positive and -negative bacteria as
well as in viruses. By far the best studied SAgs are found in the human pathogens S. aureus
and S. pyogenes, but these toxins can also be found in other streptococcal species, the
bacterium Mycoplasma arthritidis [173] and Yersinia pseudotuberculosis [174] as well as
rabies [175], mouse mammary tumor [176] and human endogenous retro- [177,178]
viruses. Due to the vast knowledge of the staphylococcal and streptococcal SAgs our
primary focus will be on those toxins.
The staphylococcal SAg nomenclature is based on the ability of the toxin to also cause
food poisoning (including emesis), and are thus described as staphylococcal enterotoxin
(SE) or -like (SEl) molecules. The SE SAgs have been scientifically shown to induce
emesis, whereas SEl toxins have similar tertiary structure but not been shown to have this
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feature [179,180]. The exception to this is the SAg primarily implicated in menstrual toxic
shock syndrome (TSS), TSS toxin-1 (TSST-1) [181]. Despite nomenclature being
primarily based on emetic properties, all SEs, SEls and TSST-1 have the ability to activate
T cells based on TCR Vβ specificity (with the exception of SEH, which targets the TCR
Vα chain [182–184]). Another group of related toxins, termed the staphylococcal
superantigen-like proteins (SSLs; originally named staphylococcal enterotoxin-like [SET]
proteins) were shown to have high sequence similarity to the staphylococcal SAgs but were
not enterotoxic or superantigenic [179,185,186]. There are currently over 20
staphylococcal SAgs and with genomes being ‘mined’ for these toxins, more are likely to
be discovered.
Streptococcal SAgs were first named due to their ability to induce fever (e.g. streptococcal
pyrogenic exotoxin [Spe]) and later based on their mitogenic (streptococcal mitogenic
exotoxin [Sme]) or superantigenic (streptococcal SAg [SSA]) activities. Upon the
screening of numerous streptococcal genomes (including Group A, C and G streptococci)
an abundance of streptococcal SAgs and numerous alleles were discovered and
subsequently characterized and named. Despite sequences being extremely similar (or the
same), numerous toxins were differentially named, which caused confusion in the field of
streptococcal SAg research for years. Recently, Commons et al. analyzed the literature and
clarified a number of these errors [187]. This clarification has led to the classification of
14 streptococcal SAgs, SpeA, C, G, H, I, J, K, L, M, N, O, P, SSA and SmeZ, of which 11
are found in GAS (all except SpeN, O and P). There is also allelic diversity within specific
SAgs in which 91 unique nucleotide sequences encoding complete streptococcal SAgs
were found to belong to those 14 SAgs mentioned above. By far the greatest allelic
diversity was discovered in SmeZ which had over 50 variants, some of which were
nonfunctional due to a single base pair deletion forming a truncated protein [187–189].
Between the staphylococcal and the streptococcal SAgs, a family of toxins (termed the SAg
superfamily) with highly conserved tertiary structure and apparent functional redundancy
has been described [179,190]. The SAgs produced by these organisms can be categorized
into five groups (Group I – V) based on their amino acid sequences. Interestingly, SAgs
generally do not cluster based on the organism that produces them, indicating potential
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horizontal gene transfer between organisms throughout their evolution. TSST-1, the nonemetic, causative agent of menstrual staphylococcal TSS [191], and SEl-X are the only
SAgs in Group I [192]. Group II SAgs include common causes of non-menstrual TSS such
as SEB, SEC [193,194] and SpeA [17]. Group III contains only staphylococcal SAgs such
as SEA, SED and SEE, all of which are known to be emetic [195]. Group IV SAgs are all
from streptococcal species and include the well-studied SpeC. Group V consists of mostly
staphylococcal SAgs from the SEl group, other than SEI and SpeI. The differences between
SAg Groups I – V are not only their amino acid sequences, but also the engagement of host
immune receptors, which will be discussed below.
The majority of staphylococcal and streptococcal SAgs are found on mobile genetic
elements. The staphylococcal SAgs are generally found on prophages, plasmids and
pathogenicity islands (PI), discrete chromosomal accessory genetic segments harboring
many virulence factors, but lacking essential genes [196–198]. The same is observed with
streptococcal SAgs in that they are primarily found on phage-like elements [43,199]. In
both organisms, however, there are SAgs encoded on the core genome, such as selx in S.
aureus [200] and speg, spej and smez in S. pyogenes [199]. The presence of SAgs on mobile
genetic elements would suggest the possibility of SAg gene movement between organisms.
This has indeed been shown with streptococcal species in which SAgs on a lysogenic phage
were transferred between GAS strains [201] and even to GCS [202]. These results support
the idea of horizontal transfer of SAg genes between species, contributing to their
evolution, as well as incorporation of these toxins into the core genome if the bacteria stand
to benefit.
Superantigen structure and binding to host immune receptors
Numerous crystal structures of SAgs, either alone or in complex with immune components
have been solved and have aided in our understanding of SAg interactions. For the purpose
of this introduction, we will focus primarily on streptococcal SAgs. The crystal structures
of SpeA [203], SpeC [204], SpeH [205], SpeI [206], SpeJ [207] and SmeZ [205] have all
been solved, and for those that have not, structural modeling can be done using previously
crystalized SAgs as a scaffold backbone.
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The immune-stimulating properties of SAgs stems from their simultaneous interaction with
the host MHC II molecules on the surface of antigen presenting cells (APCs) and TCR Vβ
chains. The classical SAg structure (which pertains to most streptococcal and
staphylococcal SAgs) consists of a protoxin with a secretion signal that is cleaved from the
N-terminus upon export via the general Sec-dependent secretory pathway. The mature
exotoxin is between 22 – 29 kDa and is stated to be highly resistant to heat, acidity and
desiccation. More specifically, all classical SAgs from S. aureus and S. pyogenes follow a
similar tertiary structure, in which the N-terminus contains a mixed β-barrel domain with
Greek key topology also known as an oligonucleotide/oligosaccharide-binding (OB) fold.
This domain binds the major histocompatibility complex (MHC) class II -chain in a lowaffinity interaction and the TCR. The C-terminus is a β-grasp fold and contains a twisted
β-sheet capped by a central α4-helix. This β-grasp fold contains the zinc-dependent, highaffinity MHC binding interface for SAgs in Groups III – V. A section of the N-terminus
also extends over the top of the C-terminus packing against a four-strand antiparallel
twisted sheet resulting in a tight architecture which likely makes these molecules resistant
to the conditions stated above (Figure 1A). Residues from this area are also involved in
TCR interactions. The overall architecture varies slightly between SAgs, which explains
their preference for certain TCR Vβ chains and MHC II interactions.
Binding of the TCR and the MHC II by SAgs differs significantly from conventional T cell
activation (Figure 1B) and can be generally categorized based on Groups I – V. What is
generally understood with TCR Vβ interaction is that binding of the complementaritydetermining region (CDR) 2 loop appears to be a requirement for all staphylococcal and
streptococcal SAgs and governs TCR Vβ-specificity, whereas other binding sites in the Vβ
domain are responsible for stabilizing the interaction [208]. TSST-1, a Group I SAg,
uniquely binds the MHC α-chain through a peptide-dependent, N-terminal low-affinity
binding domain [209,210] and the TCR Vβ chain CDR2 region as well as the third
framework (FR) region, in an energetically cooperative manner [208,211,212] (Figure
1C). Group II SAgs – including SpeA, SEB, SpeH and SSA – bind the MHC II α-chain
through a peptide-independent, low-affinity, N-terminal site [213] and the TCR Vβ chain
through conformational dependent mechanisms (largely independent of specific Vβ amino
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Figure 1. Superantigen structure and immune complex formation.
A. Ribbon diagram of the superantigen (SAg) SpeC (PDB: 1HQR) [204] with colourhighlighted immune interaction domains. N- to C-terminus: T cell receptor (TCR; blue),
low-affinity MHC class II (yellow), linking central α-helix (green) and zinc (cyan)dependent high-affinity (red) MHC class II interacting domains. B. Conventional TCR (αchain, blue; β-chain, yellow) recognition of a peptide (black) in complex with MHC class
II (α-chain, red; β-chain, green) (PDB: 1FYT) [214]. C – G. Binding of TCR and MHC
class II by representative SAgs from Groups I – V built on the backbone of SEB/MHC/TCR
(PDB: 4C56) [215]. C. TSST-1 interacting with human TCR Vβ 2.1 (PDB: 2IJ0) [211] and
HLA-DR1 MHC class II [209]. D. SEB interaction with TCR Vβ19 and HLA-DR1 (PDB:
4C56) [215]. E. SEH high-affinity MHC class II interaction with HLA-DR1 (PDB: 1HXY)
[216] and TCR Vα27 (PDB: 2XNA) [183]. F. SpeC interaction with high-affinity MHC
class II HLA-DR2a (PDB: 1HQR) [204] and human TCR Vβ2.1 (PDB: 1KTK) [217]. G.
SEK interaction with human TCR Vβ5.1 (PDB: 2NTS) and MHC class II high-affinity
interaction site based off of SEI bound with HLA-DR1 (PDB: 2G9H) [218].
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acids side chains) restricted to CDR2 and hypervariable (HV) region 4 [217,219,220]
(Figure 1D). Group III contains only S. aureus SAgs (such as SEA, SEE and SEH) and
these SAgs bind MHC II with both the low- and high-affinity interactions [216,221–223].
Along with the crystal structure of SEH in complex with a TCR Vα chain [182,183]
(Figure 1E), two other Group III SAgs have been recently crystalized with TCR Vβ to
help define this interaction. SEA and SEE have highly similar amino acid sequences,
structures and TCR Vβ interacting interfaces. A shallow groove in the SAg interacts mainly
with the CDR2, FR3 and HV4 and to a lesser extent the CDR1 and FR4 regions of the TCR
Vβ [224,225]. The Group IV SAgs are all produced by streptococci and include the wellstudied SpeC. Like Group III SAgs, these toxins also contain a high-affinity MHC binding
domain [204]. Our laboratory has also outlined a low-affinity binding site for SpeC, which
acts similarly to the Group II SAgs [226]. Mutation of the SpeC high-affinity MHC-binding
site via amino acid replacement of crucial zinc-binding residues (aspartic acid at position
203) significantly reduces, but does not extinguish, immune activation [227]. SpeC
engagement of the TCR is highly specific for human TCR Vβ2.1 in that it engages all
hypervariable loops (CDR 1 – 3 and HV4). There are single residue insertions in the CDR
1 and 2 loops of the human TCR Vβ2 which SpeC makes extensive networks of
intermolecular contacts with [217], which are energetically and functionally important for
this interaction [228] (Figure 1F). Lastly, Group V SAgs include mostly staphylococcal
SAgs (such as SEl-K and SEI) and SpeI. The best characterization of a Group V SAg and
MHC is that of SEI with HLA-DR1 in which binding occurs similarly to Group IV SAgs
[218]. Probably the most unique feature of this SAg group is the existence of an additional
~15 amino acid loop between the third α-helix and the eighth β-sheet (α3-β8 loop) that has
been shown to be crucial for T cell activation [206]. For SEl-K, this loop has a recognition
site on the apical loop of the human TCR Vβ5.1 FR4 that is necessary for binding and
required for functional activation of this T cell subset [229] (Figure 1G).
Another important consideration is the specificity of the SAg-TCR interaction. If a SAg
targets a variety of TCR Vβ chains, then it is considered to have less specific interactions,
and if it targets only one TCR Vβ chain with high affinity then it is considered very specific.
The least specific SAgs (including SEB and SEC) make hydrogen bonds with the mainchain atoms of the TCR Vβ CDR2 and HV4 loops [219,220] (Figure 1D). Slightly higher
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specificity exists for SpeA, in which it contacts more hypervariable loops than those
mentioned previously and additional hydrogen bonds are formed between side-chain atoms
from both TCR and SAg [217]. Upon further restriction of TCR Vβ interaction, the entire
hypervariable portion of the TCR Vβ chain is engaged. The best described example would
be SpeC, in which the Vβ it engages – human TCR Vβ2.1 – has non-canonical residue
insertions that it also makes contacts with, providing a unique binding site [217] (Figure
1F). The highest specificity is seen when SAgs make contacts with unique features within
the CDRs and FRs of the TCR Vβ, such is the case with TSST-1 and SEl-K [211,229]
(Figure 1C and 1G).
The culmination of this work is that we can now use crystal structures to visualize the full
ternary complex (MHC/SAg/TCR). In fact, SEB was recently crystalized in this complex
demonstrating that the SAg adopts a wedge-like position allowing for interaction of the
TCR α chain with the MHC, but preventing contact with the peptide so T cell activation is
peptide-independent [215] (Figure 1D). Although crystal structures of actual full ternary
complexes do not exist for other classical SAg groups (a ternary complex involving MAM
has been published [230]), we can use molecular modeling to postulate what is likely
occurring. TSST-1 (Group I) generates contact with MHC and TCR as described above,
but unlike SEB, there is thought to be no interaction between MHC and TCR due to the
relative orientation with the SAg/MHC and the SAg/TCR interactions (Figure 1C). The
SAgs with high-affinity, zinc-dependent MHC binding sites (SpeC, Group IV [Figure 1F];
SEl-K, Group V [Figure 1G]) are thought to bridge TCR and MHC similar to TSST-1 in
that there is no actual contacts made between MHC and TCR. SpeC, which also has a lowaffinity MHC site [226], is also able to bridge MHC/TCR similar to Group II (Figure 1F).
The last consideration of this immune complex (SAg/MHC/TCR) formation is the
energetic favorability of these interactions. The optimal affinity range of MHC/TCR
interactions required for T cell activation is thought to be between between 10-7 to 10-5 M
[231]. Although diverse, all of the above mentioned SAg/MHC/TCR interactions are able
to achieve affinities within this range [206,228,232,233], allowing these toxins to potently
activate T cells, which is the currently understood biological role of SAgs.
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Recently, the classical view of SAg/MHC/TCR binding has been challenged by the
potential interaction of SAgs with the co-stimulatory CD28 molecule [234]. CD28 is
expressed on the T cell surface and interacts with the B7 molecules CD80 and CD86 [235].
It was demonstrated that SEB binds CD28 with micromolar affinity and that this interaction
was required for induction of proinflammatory cytokine genes and a structural model was
also suggested with SEC [236]. A CD28 mimetic peptide was also shown to be protective
in a murine lethal challenge model with SpeA and S. pyogenes infection [237]. A potential
criticism of this model is that all data thus far have been derived from low-affinity MHC
interacting SAgs, while the majority (9 of 11) of streptococcal SAgs also have a zincdependent, high-affinity MHC binding interface. The suggested SAg-CD28 interface
would sterically hinder this interaction, and thus it is unclear whether or not CD28
interaction plays a role in immune-complex binding or if there is an alternative CD28
binding site.
Cell signaling induced by superantigens
SAgs activate far greater proportions of naïve T cells compared to classical antigen
presentation due to their affinity for the MHC and specific TCR Vβ chains. Stimulation, as
mentioned above, occurs by SAgs binding both the MHC II molecule on the surface of
APCs and the TCR on T cells in a Vβ-dependent manner, resulting in extensive T cell
clonal proliferation and activation. Individual SAgs bind different TCR Vβ repertoires that
can be very specific for a single V, or more promiscuous leading to a characteristic
‘fingerprint’ associated with that SAg. It is important to note, however, that research has
also indicated TCR Vβ response can vary with stimulation strength, whereby a broader
repertoire of Vβ-response can be seen at higher SAg concentrations or through presentation
with an MHC molecule that binds with higher affinity [238]. Regardless, the consequence
of this interaction is activation of the bound T cells and downstream signaling that results
in the release of numerous cytokines into the local immune environment. SAgs have been
shown to activate multiple T cell subsets including both CD4+ and CD8+ T cells [239], γδ
T cells [240] and invariant natural killer T cells (iNKT) [241]; however, it is not known
whether intracellular signaling in these subsets differs. By far, the best studied SAg-
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mediated T cell activation cell-signaling pathways has been in traditional αβ T cells, which
is outlined below.
Binding of SAgs to MHC and TCR are thought to induce a similar signaling cascade as
normal antigen recognition. Upon interaction of the TCR/MHC (by a SAg), Lck (a src
family protein tyrosine kinase associated with the cytoplasmic tail of the co-receptor
molecules CD4/CD8) is thought to be dephosphorylated on a negative regulatory tyrosine
(Y505) by CD45 upon recruitment of the co-receptor molecule to the TCR/CD3 complex.
Lck then phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the
cytoplasmic tail of the CD3 complex, which becomes the site for the recruitment and
activation of ZAP-70 (Syk family tyrosine kinase). Activated ZAP-70 phosphorylates
tyrosine residues on the cytoplasmic portion of the transmembrane adaptor linker of
activated T cells (LAT). This cascade leads to activation of phospholipase C (PLC)γ, which
converts phosphatidylinositol 4,5-bisphosphate (PIP2) to the second messengers inositol
triphosphate (IP3) and diacylglycerol (DAG). IP3 is responsible for increasing intracellular
Ca2+ and DAG activates protein kinase C (PKC) and Ras. Intracellular Ca2+ drives
calcineurin dephosphorylation of NFAT which allows translocation to the nucleus. DAG
leads to activating of the Ras/Raf-1/MEK/ERK pathway which leads to transcription factor
AP-1 (Fos/Jun) translocation to the nucleus. DAG also plays a role in PKC activation which
eventually leads to NF-κB (Rel and p50) translocation to the nucleus and upregulation of
gene transcription. A second Lck-independent signaling pathway was also shown to be
present during SAg-mediated T cell activation. The G protein Gαq11 is thought to activate
another phospholipase (PLCβ), which also cleaves PIP3 into IP3 and DAG which, in turn,
would continue the cascade similarly from there. T cell activation drives upregulation of
activation markers (such as the IL-2 receptor α-chain; CD25), adhesion molecules and
induces expression of numerous cytokines. The induction of NFAT, AP-1 and NFκB drive
the expression of proinflammatory cytokines such as IL-1, IL-2, IL-6, IFNγ and TNFα
[242–245].
The response of T cells to SAgs can be separated into three distinct phases: (1)
activation/proliferation, (2) deletion and (3) unresponsiveness/anergy [239,246]. The
aforementioned signaling cascade results in T cell proliferation (cell division) and
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activation (secretion of cytokines and chemokines). This is the first phase and lasts
generally from the initial hours of exposure to around two days. The newly expanded T
cell subset then undergoes rapid deletion (phase 2) [247–249]. The mechanism behind this
sudden decrease in cell numbers is still not entirely clear, but it is thought to be due to
Fas/FasL-mediated activation-induced cell death [250]. The last phase is a prolonged state
(can last for months) of unresponsiveness termed ‘anergy’, whereby the cells that did not
undergo deletion are still present, but they are unable to be restimulated by SAgs and other
T cell mitogens (anti-CD3 antibodies, concavalin A, etc.) [251]. This state has been
extensively studied in murine models of SAg-exposure [251–255] and has been shown in
human lymphocytes [256]. Importantly, depletion of specific TCR Vβ T cell subsets has
been observed in humans with streptococcal diseases [257,258], indicating that this
phenomenon can occur during streptococcal disease manifestation.
Although numerous cell types can act as APCs for the SAg/MHC/TCR ternary complex,
the effect of different cell types as APCs remains poorly studied. It seems that SAg
stimulation of APCs leads to a signaling cascade similar to that seen in traditional
MHC/TCR interaction. This is similar to what was presented above whereby a tyrosine
kinase (in this circumstance Syk) is phosphorylated upon immune complex interaction
which results in intracellular Ca2+ increase due to PLC activation [259]. This has been
shown to lead to cytokine expression in APCs as well including TNF, IL-6, IL-10 and IL12
as well as an increase in numerous surface markers [260,261]. When the APC is a B cell,
it has been shown that SAg interaction increases MHC mRNA [262] and non-specific,
polyclonal Ig response [263]. It has also been demonstrated that different SAgs interact
better with specific human MHC (HLA) molecules [264–266]. These data indicate that
APCs play an important role during SAg immune stimulation, and that further work is
needed to elucidate the differences between this diverse group of cells and the impact they
may have in disease progression.
Superantigen disease associations
Human evidence to support the involvement of SAgs in specific diseases generally comes
in one of three forms: epidemiological studies showing an increase in proportion of disease
associated with strains encoding specific SAg genes, serological studies detecting

27

seroconversion to SAgs, or TCR Vβ skewing patterns in patients that are associated with a
specific SAg.
The disease originally associated with SAgs was scarlet fever, which was first shown to be
caused by erythrogenic toxins – later revealed to be SAgs – produced by GAS [172]. It is
thought that the rash associated with scarlet fever is the result of immune stimulation by
bacterial SAgs. Although no single toxin is consistently associated with scarlet fever,
SpeA, SpeC and SSA seem to have the highest correlation with the disease, generally
determined by PCR amplification of the SAg genes from patient-isolated strains [267–
270].
The dysregulated immune response in STSS has led to the suggestion of SAg involvement
for decades. A large majority of supporting evidence involves epidemiological data that
has associated GAS serotypes encoding specific SAgs with cases of STSS. Primarily, speA
and speC have been associated [270–276]; however, other groups have also found other
SAgs (speJ, speK, speM and ssa) to be involved [277–280]. Despite this evidence, other
analyses have reported no apparent difference in SAg gene frequencies between invasive
and non-invasive S. pyogenes isolates [281–284]. One study was able to detect SpeA in the
sera from two patients with STSS [285] and another study attributed SmeZ ( either alone
or in combination with SpeJ) as the causative agent in STSS [20]. Lack of neutralizing
antibodies has also been theorized to be a risk factor for STSS and other severe
streptococcal disease. Eriksson et al. showed low anti-SAg antibody titres in patients with
STSS and bacteremia compared with those from uncomplicated erysipelas [286], whereas
Basma et al. showed higher neutralizing anti-SAg antibodies in those with both severe and
non-severe invasive GAS disease compared to matched healthy donors [287]. Numerous
studies have also detected the unique ‘fingerprint’ that SAgs leave on the TCR Vβrepertoire, matching SAgs present in isolates from GAS severe infections to proliferation
or depletion in specific TCR Vβ subsets [257,258,288]. These data, although not entirely
conclusive, do suggest that SAgs play a significant role during STSS and potentially other
severe and invasive GAS infections in humans.
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There is also support for a superantigenic role in Kawasaki Disease, a systemic vasculitis
that affects young children (generally less than 5 years old) and can lead to coronary artery
damage [289]. A number of studies have analyzed TCR Vβ-skewing patterns, anti-SAg
antibody titres, and PCR analysis to detect SAg in stool samples from patients, all which
suggest a role for SAgs in this disease [290–296]. Some groups, however, have failed to
show evidence of SAg involvement with Kawasaki Disease. These findings are mainly
associated with the lack of anti-SAg antibodies [297–299] or the fact that oligoclonal
expansion of B cell IgM transcripts were detected in peripheral blood of patients with
Kawasaki Disease, indicating disease pathogenesis from a conventional antigen and not a
SAg [300]. The overall findings seem to support a role for SAgs in the disease pathogenesis
of Kawasaki Disease, but with some conflicting results and no direct mechanism available,
further research will have to be done to elucidate the role for these toxins in this disease.
Guttate psoriasis is an inflammatory skin disease that is commonly associated with flareups after upper respiratory tract infections with β-hemolytic streptococci [301]. Some
studies observe TCR Vβ-restricted T cell stimulation in the disease [302–304], but others
have indicated oligoclonal T cell infiltration in psoriasis lesions suggesting a role for a
more conventional antigen and potential autoimmunity [305]. It is possible that SAgmediated activation of T cells could be driving an autoimmune response; however, further
research on this topic is required.
Much like the implications for guttate psoriasis, ARF is a known post-streptococcal
autoimmune sequela that can affect multiple tissues. Cross-reactive immune sera to these
tissues are thought to be the etiological agent, and SAgs may potentially stimulate
autoreactive immune cells. There is high correlation between M18 ARF S. pyogenes
isolates and the speL and speM SAg genes as well as antibodies in ARF patients to these
SAgs [306,307]. However, it was also shown that antibodies against SAgs did not predict
susceptibility in Australian Aboriginals [308], indicating that other factors may also play a
role in ARF development.
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1.7.10

Other virulence factors

The above mentioned list of GAS virulence factors is by no means an exhaustive list, but
does describe some of the best studied factors. S. pyogenes has numerous elements that
contribute to virulence that are not discussed here. For more information on such factors
please refer to other reviews that give a much broader view of S. pyogenes virulence
[2,29,309].
Genetic regulation in S. pyogenes
The regulation of S. pyogenes gene expression is controlled by 13 known two-component
regulatory systems (TCSs) and at least 30 stand-alone transcriptional regulators. There is
extensive interplay between these elements making it an extremely complex system. For
this reason, we will be focusing primarily on the best-studied virulence-associated systems
and their impact on gene expression. For a more in-depth analysis, McIver and colleagues
have provided excellent reviews on this topic [106,310].
The best characterized TCS in S. pyogenes is CovRS (formerly CsrRS). Like other TCSs,
CovRS is composed of a sensor histidine kinase, CovS, that is able to sense external signals
(such as Mg2+ and host antimicrobial peptides [311,312]) and modify a response regulator,
CovR, that regulates gene expression of numerous virulence factors. Phosphorylation of
CovR by CovS results in dimerization and the ability to directly bind DNA at the promoter
region of targeted genes [313,314]. The CovRS TCS is known to influence up to 15% of
all GAS chromosomal genes, including the hyaluronic acid capsule, SpeB cysteine
protease, streptokinase and SLS [164]. CovR is generally a repressor of many virulence
factors, and mutational analysis of CovRS TCSs demonstrates that a non-functioning
CovRS switches S. pyogenes to a hypervirulent phenotype in which SpeB gene expression
is reduced, and numerous virulence factors are upregulated, including SpeA and SLO
[91,315]. It has been suggested that the transition from localized to systemic infections by
the globally disseminated M1T1 GAS serotype is due to this CovRS mutation leading to
the hypervirulent phenotype [316]. The complete role that CovRS plays during human
infection is not completely understood, and since strains are still able to exist with and
without a functional CovRS TCS, more research on this topic is warranted. What is known,
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is that this TCS impacts a large proportion of GAS genes and a broader understanding of
its influences will aid in our understanding of this complex pathogen.
‘Stand-alone’ regulators are those that control gene expression in response to outside
stimulus yet the exact signal and cognate sensory element remain undefined. There are
three main ‘stand-alone’ regulators in S. pyogenes and they include: Mga (the multiple
gene regulator of GAS); RALPs (RofA-like proteins); and Rgg/RopB.
Mga was originally classified as virR (virulence regulator) by one group that found M
protein negative M12 isolates with a mutation upstream of the emm gene [317]. Another
group found a comparable locus in a M6 strain of GAS and called it mry (M protein RNA
yield) [318]. It was eventually determined that these were both actually the same regulator
and the culminating name was changed to Mga [319,320]. One of the two divergent mga
alleles (mga-1 and mga-2) can be found in every strain of GAS [321,322] and it is known
that Mga transcriptionally activates genes during exponential growth of the organism
[106]. Along with the M protein, Mga also upregulates the virulence factors ScpA and SIC,
fibronectin-binding and collagen-like proteins as well as carbohydrate utilization and
metabolism genes [106]. It is important to note that other pathogenic streptococci have
Mga orthologs [323,324] and there is evidence that Mga plays a role in the early acute
phase of infection in vivo [325–328].
The RALP family includes four proteins found in GAS (RofA [RALP1]; Nra [RALP2];
RALP3 and RivR [RALP4]) as well as orthologous members in other pathogenic
streptococci [106,329]. All analyzed GAS strains have at least RofA or Nra, and potentially
several other RALP members resulting in RALP-member and RALP-regulation variability
[322,330]. Genes regulated by RALP include microbial surface components recognizing
adhesive matrix molecules (MSCRAMMs; such as those for pilus biosynthesis,
fibronectin-binding proteins), hemolysins (SLS), proteases (SpeB) and SAgs (SpeA) [330–
333]. The RALP family is primarily involved during the transition from exponential to
stationary growth and impacts host-pathogen interactions and avoidance of host cell
damage [330,333,334].
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The Rgg/RopB transcription regulator family of DNA-binding proteins can be found in
both GAS [335,336] and closely related organisms [337–341]. This response regulator
family seems to play a role in modulating virulence at times of nutritional limitation and
stress. Rgg/RopB plays its largest role in post-exponential growth, but there is high strain
variability in that it can impact as few as two core genes or as much as >30% of the genome
[342,343]. Of the genes influenced by Rgg/RopB, there seems to be a repression of mgarelated proteins (SIC, M protein, etc.) as well as SLO and streptokinase, and activation of
virulence factors such as SpeB, the SAg SpeG, the α2-macroglobulin-binding protein
[76,343–346] and proteins involved with amino acid catabolism [344,347].
Animal models of Group A Streptococcus infection
No in vitro, in situ or in silica model is able to replicate the extreme complexities that exist
within a host, and thus in vivo infection models are used in essentially all pathogenesis
research. The study of S. pyogenes is no different, and in addition to this, a number of
factors make working with this pathogen more difficult. The first issue is that GAS is a
human-specific pathogen, and thus a number of its virulence factors have evolved to
interact with only human immune components. Therefore, regardless of the model used,
there is likely to be an issue with proper interaction of bacterial and host factors. Second,
this organism can cause numerous types of infections of varying severity at different
locations in the host. Consequently, numerous models are required to assess factors
involved with each of these infections, resulting in further complexities. Lastly, the strain
to strain variability in this organism is extensive, and thus there is no reference strain that
best exemplifies all other strains. These difficulties have not stopped researchers from
trying to understand this organism; on the contrary, there are numerous models from
invertebrates to non-human primates that have been extremely helpful in revealing the
complexities of host-pathogen interactions. The focus here will be on one of the beststudied models, the murine model, as well as the most characteristic of actual human
infection, the non-human primate model.
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1.9.1

Murine models of infection

Mouse models present an excellent opportunity to study host-pathogen interactions. As
mammals, they contain both an innate and adaptive immune system that are similar to that
of humans. In addition, they are relatively inexpensive to purchase and house, quick to
reproduce, mature rapidly and there are numerous tools available to aid in the study of
almost any aspect of murine biology. Mice can also be bred to select for desired traits, and
can be genetically altered to express functional human genes [168,348]. For these reasons,
they have been extensively used in pathogenesis research.
Murine streptococcal subcutaneous infections, pioneered by the modern ulcer and air sac
models [349,350], mimic a broad range of highly inflammatory localized soft tissue
lesions. Strengths include rapid bacterial proliferation and extensive recruitment of
inflammatory innate immune cells which imitates what is seen in human infections [349–
351]. However, a major limitation of these models is that histopathology of the infections
is not the same as that observed in human manifestations due to the thinner murine
epidermal layer. Also, for S. pyogenes pathogenesis mice may be a good model for the
innate, but arguably not the adaptive, immune response since a protective immune response
does not develop after resolution of the infection [352]. Regardless of the limitations, this
model is considered to be one of the most versatile and useful models for studying S.
pyogenes pathogenesis.
Murine models of systemic disease differ in their inoculation route and are generally
performed by either intravenous (IV), intraperitoneal (IP) or intramuscular (IM) injections.
These models are heavily used due to their technical simplicity [100,353,354], although
direct inoculation into the bloodstream, peritoneal cavity or muscle bypass a crucial barrier
that GAS normally must traverse. It is for this reason that intratracheal (IT) administration
of bacteria has become more popular. Requirement of the bacteria to traverse the lung
epithelial more closely resembles human infection whereby sepsis occurs after a localized
infection in soft tissue [132,355,356]. Researchers have found that IT inoculation is more
efficient at investigating the role of virulence factors in inducing systemic disease [357–
359]. It is important to note that mouse strain, gender and genetics all play an important
role in regards to systemic infection and the absence of adaptive immunity also does not
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impact infectivity [360]. An additional implementation to better mimic human infections
is the use of transgenic mice expressing human genes. Due to S. pyogenes being a human
specific pathogen, certain virulence factors are tailored to interact with only human
immune components and expression of these molecules in a murine system has been shown
to increase susceptibility of mice to systemic infections [168].
As mentioned previously, SAgs are associated with TSS and administration of these toxins
to mice is used as a model to study TSS. However, SAgs interact poorly with murine
immune components [361] and sensitizing agents such as D-galactosamine, LPS or
actinomycin were previously used to help induce this disease [362,363]. It was later found
that these sensitizing agents induced a viral hepatitis-like liver injury which is not
characteristic of human TSS (multi-organ dysfunction phenotype, not just a single organ)
[364–367]. It was shown that mice expressing human leukocyte antigen (HLA) transgenes
better replicated the human disease, and has thus become the gold-standard [368].
Numerous studies have since used this model to further develop our understanding of the
role of HLA-molecules in both bacterial- and toxin-induced sepsis [264,265,369,370]. It
has also been shown that different HLA types can render humans either protected or
susceptible to invasive GAS infections [371], increasing the relevance of this transgenic
mouse model.
The most prevalent host-pathogen interactions involving GAS are pharyngitis and
nasopharyngeal asymptomatic carriage [4,23]. This indicates that the primary reservoir for
S. pyogenes is the human upper respiratory tract, more specifically, the mucosal-associated
lymphoid tissue known as Waldeyer’s ring (including the tonsils). It is important to note
that mice lack this tissue, but instead have a functional homologue known as the nasalassociated lymphoid tissue (NALT) inside their nostrils [372–374]. This, and the
surrounding tissue (ethmoid turbinates, maxillary sinus and septum) make up what is
known as the complete nasal turbinate (cNT) (Figure 2). Murine models of nasopharyngeal
GAS infection/carriage involve administering a bolus of bacteria into the nares to seed this
tissue and have been extensively used [110,354,375–377]. Numerous factors can also play
a role in determining efficiency of infection, including: quantity and volume injected,
duration of infection, bacterial strain, and mouse strain used. Inoculum volume is generally
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Figure 2. The murine complete nasal turbine.
Coronal transverse sections of formalin-fixed mouse head stained with hematoxylin and
eosin. Indicated architecture is labelled: ethmoid turbinates (ET), maxillary sinus (MS),
nasal-associated lymphoid tissue (NALT) and the septum. The collective tissue
environment is referred to as the complete nasal turbinates (cNT).
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less than 20 µL as volumes greater than this have been shown to seed bacteria into the lung
and cause pneumonia [376]. Duration of infections vary on amount of bacteria inoculated,
but mice generally clear infections in 7-14 days, with some potentially harboring bacteria
for longer [110,376,377]. Bacterial quantitation can be assessed using numerous methods:
from sacrifice and tissue procurement for end point counts, nasal shedding assay (whereby
nares are pressed against agar plates for bacterial enumeration) and bioluminescent
imaging. The murine cNT is also an ideal location for live imaging and genetically
engineered bioluminescent strains of GAS have been used in this model [375,378].
Analysis of the immune system in response to GAS nasopharyngeal infection has
demonstrated a CD4+ T cell-mediated clearance of bacteria that also involved neutrophils
[354,379–381]. This demonstrated that both innate and adaptive immune cells can
contribute to clearance of S. pyogenes in this model. It is important to note that the majority
of intranasal infection models have used conventional laboratory mice (C57Bl/6, BALB/c,
FVB, CD1, etc.) [375,376,378,379,382], however, it was recently shown that transgenic
mice expressing human MHC II (HLA-DQ8) are much more susceptible to infection by S.
pyogenes and may represent a much more relevant model [377]. However, limitations
include the relatively short duration of infection/colonization, the differential architecture
of the cNT from human tonsillar tissue, technical difficulty in isolating cNT tissue and the
limited number of S. pyogenes strains that have demonstrated the ability to infect this
tissue.
The limited duration of GAS nasopharyngeal infection was an issue not easily solved by
making modifications to the existing model. However, since S. pyogenes is known to
colonize the female genital tract [383–385], an alternative approach to study this hostpathogen interaction was adapted from a model previously used with other mucosal
pathogens (Group B Streptococcus [386], N. gonorrhoeae [387] and Candida albicans
[388]) using estradiol-primed conventional laboratory mice (C57Bl/6 and BALB/c) [389].
Estrous phase mice are vaginally inoculated with GAS and lavages can be taken to count
bacterial load over several weeks to months. This duration, asymptomatic nature of
infection, and the non-lethal measurements of bacterial burden (and cytokines) by lavage
have allowed for the investigation of factors involved in longitudinal mucosal carriage of

37

GAS [389,390]. Limitations include strain variability, the normal microflora must be
eliminated prior to colonization, and only estrogen-treated female mice can be used [389].
1.9.2

Non-human primate models of infection

Animal infection models that resemble humans, the only known reservoir for GAS, are
extremely important for understanding host-pathogen interactions and testing of potential
therapeutics. As close biological relatives, non-human primates are a very attractive
candidate for this role. The use of baboons (Papio cynocephalus) [391] and cynomolgus
macaques (Macaca fascicularis) [89,392–394] have been used to study invasive models
such as sepsis and necrotizing fasciitis. Because of the highly similar anatomy and
physiology, much can be garnered from these models such as relative body temperature,
heart rate, blood pressure, serum chemistry, cytokine profiles and post-mortem organ
analysis.
Unlike the above mentioned mouse models of colonization, non-human primates present a
unique opportunity to establish a more human-like infection that develops a better
representative immune response with easier access to the site of infection, larger blood and
tissue samples for more analyses and importantly is more receptive to different strains of
S. pyogenes. For decades, researchers have examined the ability of GAS to infect the
oropharyngeal tissue of numerous non-human primates including: baboons [395,396],
rhesus macaque (Macaca mulatta) [397,398], chimpanzees (Pan) [399,400] and
cynomologus macaque [401], of which the latter is the current most common model. This
is because baboons and rhesus macaques do not seem to develop symptomatic pharyngitis,
but chimpanzees and cynomologus macaques do, along with most signs and symptoms
(erythema, fever, tonsillar enlargement and palatal petechiae) [402,403]. In a short time,
an immense amount of information about host-pathogen interaction has been discovered
using these models including a dynamic humoral response during infection, genetic
regulation, and energy metabolism by GAS during pharyngitis [327,392,403–407]. Despite
the cost and ethical considerations, the non-human primate model remains the most
comprehensive tool for studying host-pathogen interactions during S. pyogenes infection
and colonization.
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Group A streptococcal vaccines
Despite decades of research there is currently no licensed vaccine against S. pyogenes. The
reasons for this include: concern over vaccines containing autoimmune epitopes, strain
variability (surface molecule differences, infection site preference and severity, global
distribution) and the primary effected population. A primary goal for vaccine development
is the prevention and reduction in major GAS-associated mortality. By far the leading cause
of death associated with S. pyogenes is autoimmune RHD [4,30,36] and an effective
vaccine should aim at prevention of this disease. The epitope(s) responsible for the
autoimmune response in ARF and other autoimmune sequelae have been implicated in the
M protein, group A carbohydrate and hyaluronic acid capsule, among other GAS factors,
which has best been reviewed by Madeline Cunningham [408,409] and Jonathan Carapetis
[30]. It is for these reasons that vaccine candidates must be rigorously studied to ensure
that they do not contain these epitopes. A major setback occurred in the late 1960s after a
crude M protein vaccine was tested in children that resulted in ARF cases in the tested
population [410,411]. This result led to a United States federal ban on GAS vaccine testing
in humans, which was removed in 2006. The fact that all of the GAS autoimmune epitopes
remain elusive provides a significant hurdle to vaccine development. Demonstration of M
protein-type immunity against GAS has been known to be protective for decades [412],
making this by far the most studied vaccine candidate. The more recent demonstration of
the growing GAS emm-types (currently over 200) and the difference in their global
distribution has made the pursuit of this vaccine less logistical for global control of this
pathogen [14,49,60]. The last major concern is that approximately 95% of the population
that would benefit most from a GAS vaccine live in low- and middle-income countries [4].
This produces a significant financial burden on the project as potential vaccine
development companies may refrain from pursuing this due to a lack of return on
investment. All of these hurdles must be overcome to generate a safe, effective and
affordable GAS vaccine.
1.10.1

M protein vaccines

The realization that anti-M protein antibodies produced following natural infection could
be protective against GAS infection due to promotion of phagocytosis [412,413] spurred
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the investigation of using these molecules as potential vaccine candidates. Further analyses
indicated that antibodies against the hypervariable N-terminus were protective and not
likely to cross-react with host tissue [414]. Eventually, it was realized that protective
epitopes could be linked together to create long peptides containing many protective
epitopes against numerous emm-types. This technology led to the development of multivalent M protein-based vaccines [414–418], of which two have made it past Phase I and
Phase II clinical trials and have been shown to be both safe and effective [419,420]. Perhaps
the greatest hurdle that these vaccines must overcome however, is the high variability
(>200 emm-types) and wide distribution of the GAS emm-types [49]. Epidemiological data
[14,58,421,422] suggests that the currently developed 30-valent vaccine [418] would
protect against isolates responsible for 98% of pharyngitis cases in Canada and the U.S.,
90% of invasive isolates in the U.S., and 78% of invasive isolates in Europe. Interestingly,
protection against serotypes not in the vaccine were also demonstrated which may lead to
significant protection in other populations [423,424]. These unexpected findings further
demonstrate the potential efficacy of a multi-valent N-terminal M protein vaccine.
Another approach taken to generate M protein vaccines is the use of epitopes found on the
more conserved, C-terminal region of the protein. Research has demonstrated that the Crepeat region of the M protein is highly conserved, contains protective epitopes, and thus
represents a possible vaccine candidate. Original vaccine studies used the entire C-terminal
region of the M6 protein [425], which future investigation later focused on specific B and
T cell epitopes [426–428]. One of the best studied C-terminal vaccines is known as J8-DT,
which is comprised of a stabilized M protein B cell epitope fused to the diphtheria toxoid
(DT) to enhance immunogenicity [426]. Passive and active immunization has proven
protective in infection models [426,429,430], long-term B cell memory is induced [431],
and no host cross-reactive antibodies are generated upon vaccination [432]. Due to its
success in animal models, J8-DT is currently undergoing Phase I clinical trials [433]. A
second M protein conserved region vaccine candidate, known as StrepInCor, is a 55 amino
acid peptide modeled after B and T cells epitopes from the C2 and C3 regions of an M5
protein [427]. Vaccination with StrepInCor demonstrated mucosal and systemic antibodies
[428] which were able to opsonize several S. pyogenes strains [434] and protected mice
from infection with no cross-reactivity to cardiac proteins or other tissues [435,436].
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Despite promising in vivo animal efficacy, there have been no human clinical trials as of
yet.
1.10.2

Streptococcal superantigen-based vaccines

The known association of SAgs with TSS led to investigations of whether or not toxoid
(inactive) molecules could be used in vaccinations to prevent the onset of the disease.
Vaccination with TCR and/or MHC II binding site mutant SAg toxoids were non-lethal,
stimulated antibody responses, and were protective in a rabbit model of TSS [437,438].
Vaccination of HLA-DQ8 mice with either toxoid SpeA alone or fused to inactive SpeB
generated antibodies that protected mice from lethal wild-type SpeA challenge, and the
fusion vaccine also significantly increased survival in a S. pyogenes sepsis model [439].
This protective antibody phenotype is supported by the fact that IVIG contains neutralizing
anti-SAg antibodies and administration of IVIG in humans has been shown to reduce
mortality in cases of STSS [21,22,440]. However, the efficacy of IVIG therapy for the
treatment of invasive streptococcal disease remains controversial [441,442]. With new
understandings of SAgs and their role in both severe/invasive diseases as well as acute
uncomplicated infections and asymptomatic colonization [245], further study is warranted
in using toxoid SAgs as potential vaccine candidates.
1.10.3

Other vaccine candidates

Although M protein based vaccines are the only candidates that have made it into clinical
trials, numerous other antigens have undergone pre-clinical, animal model protection
analysis including: SpeB [439,443]; the GAS carbohydrate [444]; C5a peptidase
[110,382,445,446], SpyCEP [92], fibronectin-binding protein [447] and others
[381,433,448]. Analysis of current GAS vaccines would indicate that we are close to
having strain-specific vaccines available, but still well behind in the development of a
globally-protective GAS vaccine. Numerous antigens have proven protective in animal
models of infections and it would seem most likely that a full protective vaccine would
come from a multi-component vaccine including multiple M protein serotypes and
numerous other antigens. However, there is a difficulty in acquiring funding to pursue
Phase I clinical trials for human safety and efficacy of these vaccines. More resources
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should be allocated towards the development of GAS vaccines, as it would have a major
impact on prevention of worldwide, GAS-associated morbidity and mortality.
Rationale and Hypothesis
On a global scale, S. pyogenes is a major cause of morbidity as well as mortality, and there
is currently no licensed vaccine against this organism [4,433]. Recently, our laboratory has
determined that streptococcal SAgs play not only an important role in severe diseases, but
also in nasopharyngeal infection establishment [449]. In this model, S. pyogenes
MGAS8232, an M18 rheumatic fever clinical isolate [306], was efficient at infecting the
cNT of transgenic mice expressing human MHC II (HLA) but not conventional C57Bl/6
mice. Using genetic knockout and complementation, this infection was also found to be
dependent on the SAg SpeA. In the work to be described, we speculate that in the above
mentioned model, in vivo production of SAgs by S. pyogenes can be detected using flow
cytometric analysis of the T cell activation marker CD25 on SAg-targeted, but not other,
T cell subsets in the local immune environment. This SAg-dependent infection phenotype
also led us to hypothesize that anti-SAg antibodies – provided by either passive
immunization or active vaccination with an attenuated SpeA toxoid – would be protective
in a murine model of GAS upper respiratory tract infection. Finally, since it is known that
Vβ-specific T cell activation is a hallmark of SAg activity, we propose that these T cells
are required to be present and functional for S. pyogenes nasopharyngeal infection.
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Chapter 2: Materials and Methods
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Materials and Methods
All solutions and media were made using water purified with a MilliQ filtration system
(EMD Millipore; Darmstadt, Germany).
Ethics statements
The use of primary human lymphocytes was reviewed and approved by Western
University’s Research Ethics Board (REB) for Health Sciences Research Involving Human
Subjects (Appendix 1). Informed written consent was obtained from all donors. All animal
experiments were completed under Animal Use Protocol (AUP) Number 2011-088 in
accordance with the Canadian Council on Animal Care Guide to the Care and Use of
Experimental Animals, and was approved by the Animal Use Subcommittee at Western
University (London, ON, Canada) (Appendix 2).
Bacterial growth conditions
A complete list of bacterial strains used in this study can be found in Table 3.
2.2.1

Escherichia coli

E. coli strains were grown in Luria-Burtani (LB; EMD Millipore) broth, containing 1.5%
(w/v) agar (Thermo Fisher Scientific Inc.; Waltham, MA, USA) when required, aerobically
at 37°C. For cultures containing pET28 or pET41 plasmids, cultures were supplemented
with 50 µg mL-1 kanamycin (Sigma-Aldrich Canada Co.; Oakville, ON, Canada). A
complete list of plasmids used in this study can be found in Table 4. Frozen stock cultures
were stored in LB broth plus 25% (v/v) glycerol.
2.2.2

Streptococcus pyogenes

S. pyogenes strains were grown statically at 37°C in Todd Hewitt broth (Becton Dickinson
[BD] Biosciences; Franklin Lakes, NJ, USA) supplemented with 1% (w/v) yeast extract
(BD Biosciences) (THY). For solid media preparation, 1.5% (w/v) agar (Thermo Fisher
Scientific) was added to broth. To restore capsule, S. pyogenes MGAS8232 was grown in
THY broth supplemented with 5% (v/v) human plasma (HP). Human plasma was collected
from healthy donors and diluted 1:1 in Roswell Park Memorial Institute (RPMI; Life
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Table 3: Bacterial strains used in this study
Strain
Escherichia coli
XL1 Blue

Description

Source

Cloning Strain
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1
lac [F′proABlaclqZΔM15 Tn10 (Tetr)]

Stratagene

BL21 (DE3)

Protein Expression Strain
F- ompT hsdSB(rB-, mB-) gal dcm (DE3)

Novagen

M18 strain isolated from patient with acute
rheumatic fever

[306]

M1 strain isolated from wound of infected
patient

[450]

Streptococcus pyogenes
MGAS8232
SF370

Streptococcus pneumoniae
P1121
Serotype 23F derived from nasopharyngeal
human carriage of strain P833

Dawn
Bowdish
[451–453]
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Table 4: Plasmids used in this study
Plasmid
pET-28a(+)

Descriptiona
Protein expression vector; Nterminal His•Tag®/thrombin cut site;
Kanr

Source
Novagen

pET-28a(+)::TEV

pET-28a(+) plasmid with modified
TEV protease cleavage site; Kanr

McCormick Lab

pET-41a(+)

Protein expression vector; Nterminal GST•Tag/His•Tag®; Kanr

Novagen

pET-41a(+)::TEV

pET-41a(+) plasmid with modified
TEV protease cleavage site; Kanr

[228]

pET-28a(+)::TEV::
speA

speA inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

[377]

pET-28a(+)::TEV::
speAN20A

Asn to Ala at mutation position 20
in speA; Kanr

This Study

pET-28a(+)::TEV::
speAL41/42A

Leu to Ala mutation at positions 41
and 42 in speA; Kanr

This study

pET-28a(+)::TEV::
speAY100A

Tyr to Ala mutation at position 100
in speA; Kanr

[377,454]

pET-28a(+)::TEV::
speAN20A/Y100A

Asn (at position 20) and Tyr (at
position 100) to Ala mutations in
speA; Kanr

This Study

pET-28a(+)::TEV::
speATRI

Leu (at positions 41 and 42) and Tyr
(at position 100) to Ala mutations in
speA; Kanr

This Study

pET-28a(+)::TEV::
speATETRA

Asn (at position 20), Leu (positions
41 and 42) and Tyr (at position 100)
to Ala mutations in speA; Kanr

This Study

pET-28a(+)::
speAHEXA

Gln to His at position 19, Asn to
Asp at position 20, Leu to Ala at
positions 41 and 42, Asp to Asn at
position 45 and Cys to Ser at
position 98 mutations in speA; Kanr

[437]
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pET-28a(+)::TEV
speAHEXA

speA mutant from Roggiani et al.
[437] inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

This Study

pET-41a(+)::TEV::
speC

speC gene inserted into NcoI and
BamHI of pET-41a::TEV; Kanr

[208]

pET-28a(+)::TEV::
speG

speG inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

[377]

pET-28a(+)::TEV::
speH

speH inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

McCormick Lab

pET-28a(+)::TEV::
speI

speI inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

[206]

pET-28a(+)::TEV::
speJ

speJ inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

McCormick Lab

pET-28a(+)::TEV::
speK

speK inserted into NcoI and BamHI
of pET-28a::TEV; Kanr

McCormick Lab

pET-28a(+)::
speL

speL inserted into NcoI and BamHI
of pET-28a; Kanr

[377]

pET-28a(+)::
speM

speM inserted into NcoI and BamHI
of pET-28a; Kanr

[377]

pET-28a(+)::
ssa

ssa inserted into NcoI and BamHI of
pET-28a; Kanr

McCormick Lab

pET-41a(+)::TEV::
smeZ

smeZ gene inserted into NcoI and
BamHI of pET-41a::TEV; Kanr

[377]

pET-28a(+)::TEV::
seb inserted into NcoI and BamHI of [455]
seb
pET-28a::TEV; Kanr
a
r
Abbreviations: Kan , kanamycin resistance; TEV, tobacco etch virus protease
cleavage site
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Technologies Inc.; Carlsbad, CA, USA) 1640 media. THY media with 5% (v/v) HP was
sterilized by 0.2 µM filtration (Pall Life Sciences; Port Washington, NY, USA). Frozen
stock cultures were created by addition of 20% (v/v) glycerol to THY media.
2.2.3

Streptococcus pneumoniae

S. pneumoniae was grown in Tryptic Soy broth (TSB; BD Biosciences) statically at 37°C
in 5% CO2. Frozen stocks were prepared by addition of 20% (v/v) glycerol into TSB media.
Growth curves
S. pyogenes and S. pneumoniae strains were grown from -80°C freezer stocks and
subcultured twice (1%) in their respective medias (THY and TSB) at the appropriate
conditions stated above. Overnight culture optical densities at 600 nm (OD600) were
corrected to a value of ~0.05 in 100 mL of media. Bacteria were grown in appropriate
conditions and OD600 readings were measured every hour using a spectrophotometer (DU®
530 Life Sciences UV/Vis Spectrophotometer; Beckman Coulter Canada LP; Mississauga,
ON, Canada). Once a logarithmic growth phase was determined, the growth curve was
repeated with serial dilution and spot plating during this phase. Bacterial counts were used
to generate a linear relationship between OD600 and bacterial concentration, with a line of
best fit and equation of the slope for bacterial preparation for infection.
Deoxyribonucleic acid
2.4.1

Plasmid isolation from E. coli

Plasmid DNA was isolated from 5 mL of pelleted E. coli after growth to stationary phase
(O/N aerobic growth at 37°C). Pelleted bacteria were treated using QIAprep spin miniprep
kit (Qiagen; Hilden, Germany) or E. Z. N. A. kit (Omega Bio-Tek; Norcross, GA, USA)
as per manufacturer’s instructions. Plasmid DNA was eluted in sterile water. A complete
list of plasmids can be found in Table 4.
2.4.2

Genomic DNA isolation from murine tissue

Genomic DNA was prepared according to The Jackson Laboratory (Bar Harbor, ME,
USA). Briefly, mouse ears were notched for identification purposes prior to being weaned
(approximately two weeks after birth). Removed tissue was stored at -20°C until use.
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Tissue was added to 75 µL of 25 mM NaOH, 0.2 mM EDTA and placed in a thermocycler
at 98°C for 1 hour followed by a reduction to 15°C until proceeding to the next step. An
addition of 75 µL of 40 mM Tris HCl (pH 5.5) was then made prior to centrifugation at
4,000 × g for 3 minutes. The supernatant was then used as template for polymerase chain
reaction.
2.4.3

Polymerase chain reaction

All primers used in this study were generated by Sigma-Aldrich and are listed in Table 5.
Primers were resuspended to a final concentration of 100 µM in MilliQ water. Reactions
were comprised of 1 × high fidelity buffer (Thermo Fisher Scientific), 2 mM magnesium
chloride (MgCl2; Thermo Fisher Scientific), 3 mM deoxyribonucleotide triphosphate
(dNTP) mixture (Roche Diagnostics; Risch-Rotkreuz, Switzerland), 10 pM each of
forward and reverse primer, at least 1 pg of low complexity (plasmid) or 50 ng of high
complexity (genomic) DNA and 0.02 units mL-1 of Phusion High-Fidelity DNA
polymerase (Thermo Fisher Scientific). All reactions were completed on a Peltier
Thermocycler PTC-200 (MJ Research, Waterdown, MA, USA). Reactions were visualized
(see below) and products were purified using a QIAquick PCR Purification kit (Qiagen)
according to the manufacturer’s instructions and eluted in sterile MilliQ water.
Plasmid mutagenesis and gene amplification
Cycling for megaprimer plasmid mutagenesis and general gene amplification was as
follows: 98°C for 5 minutes as an initial denaturing step; 98°C for 30 seconds, 0.5°C per
second ramp to 53°C annealing, 53°C for 30 seconds, 0.5°C per second ramp to 72°C for
amplification, 72°C for 4 minutes and 0.5°C ramp to 98°C, repeat for a total of 32 cycles.
The final extension step was 72°C for 5 minutes and reactions were set to 4°C before
removal from thermocycler.
Mouse genotyping
Cycling for mouse genotypes were as follows: Initial denaturing step at 98°C for 4 minutes
and 30 seconds. Cycle begins with 98°C denaturing for 20 seconds, annealing at 50°C for
45 seconds, amplification at 72°C for 15 seconds; repeat cycle 29 times. Final extension
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Table 5: Primers used in this study
Primer
T7 promoter

Sequence (5′ – 3′)a
TAA TAC GAC TCA CTA TAG GG

Purpose
Sequencing

T7 reverse

CGC CAG GGT TTT CCC AGT CAC GAC

Sequencing

NcoI His TEV speA
For

CCC CCA TGG GCA GCA GCC ATC ATC
ATC ATC ATC ACA GCA GCG GCG AAA
ACT TGT ATT TCC AAG GCC AAC AAG
ACC CCG ATC CAA GCC A

Gene
amplification

BamHI speA Rev

CCC GGA TCC TTA CTT GGT TGT TAG
GTA GAC TTC AAT

Gene
amplification

speA N20A For

AAA AAC CTT CAA GCA ATA TAT TTT
CTT

Mutagenesis

speA N20A Rev

AAG AAA ATA TAT TGC TTG AAG GTT
TTT

Mutagenesis

speA L41/42A For

TCT GTT GAT CAA GCA GCA TCT CAC
GAT TTA

Mutagenesis

speA L41/42A Rev

TAA ATC GTG AGA TGC TGC TTG ATC
AAC AGA

Mutagenesis

DQA (1027) For

GAA GAC ATT GTG GCT GAC CAT GTT
GCC

Mouse
genotype

DQA (1029) Rev

AGC ACA GCG ATG TTT GTC AGT GCA
AAT TGC GG

Mouse
genotype

DQ8b (vA) For

AGG ATT TGG TGT ACC AGT TTA AGG
GCA T

Mouse
genotype

DQ8b (vii) Rev

TGC AAG GTC GTG CGG AGC TCC AA

Mouse
genotype

DR4A (1101) For

GGA GAT AGT GGA ACT TGC GG

Mouse
genotype

DR4A (1104) Rev

CCG ATC ACC AAT GTA CCT CC

Mouse
genotype

DR4B (1098) For

GTT TCT TGG AGC AGG TTA AAC A

Mouse
genotype
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DR4B (1099) Rev
a

CTG CAC TGT GAA GCT CTC AC

Mouse
genotype

Underlined nucleotides represent restriction enzyme recognition sites; bolded
nucleotides represented mutated amino acids
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was completed at 72°C for 4 minutes, and reactions were set to 4°C until removed from
thermocycler.
2.4.4

Visualization

UltraPure™ Agarose (Invitrogen, Life Technologies Inc.) at 1% or 2% (w/v) in 40 mM Trisacetate, 1mM EDTA (TAE) buffer was used to visualize DNA. Samples were mixed 5:1
with DNA loading dye (40% [v/v] glycerol, 0.25% [w/v] bromophenol blue [International
Biotechnologies; New Haven, CT, USA]) prior to gel loading. Electrophoresis was
performed for 1 hour at 100 V (Bio-Rad Laboratories Inc.; Hercules, CA, USA). A standard
DNA molecular weight ladder (1 Kb; Invitrogen) was included in each gel as a size marker.
Agarose gels were stained with 0.05% (v/v) ethidium bromide (EMD) in TAE buffer for
approximately 20 minutes and visualized using ultraviolet light (Gel Doc™, Bio-Rad
Laboratories Inc.).
2.4.5

Gel extraction

DNA was visualized as stated above and excised from agarose gel under ultraviolet light
using a scalpel. Extracted DNA was purified using QIAquick Gel Extraction Kit (Qiagen)
according to the manufacturer’s protocol. DNA was eluted using sterile MilliQ water.
2.4.6

Quantification

DNA was quantified using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific
Inc.).
Molecular cloning
2.5.1

Restriction enzyme digestion

Restriction enzyme digestions of DNA were completed as per the manufacturer’s
instructions (New England BioLabs Inc.; Ipswich, MA, USA or Roche Diagnostics).
Briefly, target DNA with 1 U enzyme µg-1 DNA in enzyme-specific buffer and 1 × bovine
serum albumin (New England BioLabs Inc.) were incubated for 2.5 hours at 37°C.
Reactions were visualized (see above) compared to uncut controls, and purified using
QIAquick PCR Purification kit (Qiagen) as per manufacturer’s instructions and eluted with
sterile MilliQ water.
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2.5.2

DNA ligation

Appropriate concentrations (100 ng:1 ng, vector:insert; 1:1 molar ratio) of purified,
restriction enzyme digested DNA products were mixed with 1 × T4 Ligase Buffer and 40
U T4 DNA Ligase (New England BioLabs Inc.) and incubated at 16°C for 1 hour. Ligation
reactions were directly transformed into rubidium chloride competent E. coli (see below).
2.5.3

Preparation of rubidium chloride competent E. coli

Appropriate E. coli culture grown in LB media aerobically overnight at 37°C (stationary
phase) were subcultured 1:100 into 100 mL PSI broth (5 g/L Bacto yeast extract [BD
Biosciences], 20 g/L Bacto Tryptone [BD Biosciences], 5 g/L magnesium sulphate, pH
7.6) and grown to OD600 0.48. Cultures were incubated on ice for 15 minutes followed by
centrifugation at 4°C for 5 minutes at 5,000 × g. The cell pellet was resuspended in 40 mL
TfbI buffer (30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium
chloride, 50 mM manganese chloride, 15% [v/v] glycerol, pH 5.8) and incubated on ice for
15 minutes. Cells were centrifuged again as mentioned above. The pellet was then
resuspended in 4 mL TfbII buffer (75 mM calcium chloride, 10 mM 3-(N-morpholino)
propanesulfonic acid [MOPS], 10 mM rubidium chloride, 15% [v/v] glycerol, pH 6.5) and
aliquots were store at -80°C until use.
2.5.4

Transformation of competent cells

Ligation reactions (see above) were transformed into rubidium chloride competent E. coli
using a heat-shock method. Competent cells were thawed on ice, ligation reaction (~10 µL)
was added and cells were incubated for 30 minutes on ice. Cells were then placed in a 42°C
water bath for 45 seconds and subsequently placed on ice for 2 minutes. Cells then had 0.9
mL LB broth added and were incubated aerobically for 1 hour at 37°C. Transformed
cultures were then spread plated (200 µL) on LB agar with appropriate antibiotics
(according to transformed plasmid; see Table 2) and grown overnight at 37°C.
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Sequencing of DNA
Sequencing was completed by the Sequencing Facility at the John P. Robarts Research
Institute at Western University in London, Ontario, Canada. Sequencing was completed
with either provided or designated primers (Table 3).
Protein production
2.7.1

Bacterial protein expression

E. coli BL21 (DE3) containing the appropriate pET expression construct (Figure 3A) was
inoculated from freezer stock into LB broth containing appropriate antibiotic (Table 2).
The culture was then grown aerobically overnight at 37°C. Overnight culture was
subcultured 1:100 into 1L LB broth containing appropriate antibiotic and grown for 3 hours
aerobically at 37°C. The bacterial culture was then induced with 200 µM isopropyl β-D-1thiogalactopyranoside (IPTG) and grown aerobically overnight at room temperature
(~25°C). The overnight culture was pelleted at 3,500 × g for 10 minutes and resuspended
in 10 mL of 20 mM Tris base, 200 mM sodium chloride pH 7.5 buffer containing 10 µL
DNaseI (Sigma-Aldrich) and 50 µL of 10 mg mL-1 lysozyme (Thermo Fisher Scientific
Inc.) and incubated on ice for 1 hour with shaking. The bacteria was then sonicated for 3
rounds with 50 pulses each, 40% duty cycle and output 4 on a Branson Sonifier (Emerson
Industrial Automation; Eden Prairie, MN, USA) with icing between each round. Sonicated
product was then centrifuged at 10,000 × g at 4°C for 10 minutes and the supernatant was
collected for gravity nickel column purification.
2.7.2

Metal affinity column chromatography protein purification

Supernatants from bacterial lysates were added to a charged (100 mM nickel sulphate) NiNTA affinity column (Novagen, EMD Millipore) and washed with 20 mM Tris base, 200
mM sodium chloride pH 7.5 buffer containing increasing concentrations of imidazole (5
mL each; 30 mM, 60 mM and 200 mM Imidazole). Fractions were analyzed by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE; see below) (Figure 3B)
and fractions found to contain an abundance of the protein of interest were pooled and
dialyzed in 1 L of 20 mM Tris base, 200 mM sodium chloride pH 7.5 three times for 1 hour
per litre. The N-terminal His6 tags were removed from the proteins by addition of either
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Figure 3. Superantigen plasmid constructs and protein purification.
A. All wild-type and toxoid SAg genes were cloned in either pET28a or pET41a expression
plasmids with the indicated purification and cleavage tags. B – D. Protein expression was
induced using IPTG from E. coli BL21 (DE3) and SAgs were purified from cell lysate
using nickel-affinity column chromatography. B. Cell lysates were applied to a NiSO4charged column and fractions were eluted using increasing concentrations of imidazole.
SAg-containing fractions were pooled, dialysed to remove imidazole and incubated with
the appropriate cleaving enzyme. C. The sample was again passed through a charged nickel
column to remove cleaved His6 tags and His6-tagged TEV. D. Fractions of purified, cleaved
SAg were collected and dialyzed into appropriate buffer and diluted to the required
concentration. All visualization was done using 12% v/v SDS-PAGE. FT, flowthrough; W,
wash; P, purified SAg protein. Column labels indicate concentration of imidazole in the
wash buffers.
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autoinactivation-resistant His7-TEV [456] or thrombin for 24 hours at room temperature.
The protein solution was then reapplied to a charged Ni-NTA affinity column (Novagen,
EMD Millipore) to remove His7-TEV and obtain a purified protein sample (Figure 3C).
Pure protein was then dialyzed three times against 1 L of 150 mM sodium chloride, pH 7.4
for one hour per litre. Homogeneity was assessed by SDS-PAGE (see below) (Figure 3D).
2.7.3

Protein quantitation

Concentration of purified protein was determined using Pierce™ BCA Protein Assay kit
(Thermo Fisher Scientific Inc.) according to manufacturer’s instructions. Briefly, the
protein of interest was mixed with working reagent, bicinchoninic acid (BCA), for
colourimetric detection of protein at an optical density of 562 nm. The protein of interest
concentration was then determined by comparing with various concentrations of a
reference protein, BSA. Optical density was read using a Synergy™ H4 Hybrid Multi-Mode
Microplate Reader (BioTek, Fisher Scientific Inc.).
Protein visualization
2.8.1

Sodium dodecyl sulphate polyacrylamide gel electrophoresis

Protein samples were mixed 3:1 with 4 × Laemmeli buffer (240 mM Tris-HCl pH 6.8, 8%
[w/v] sodium dodecyl sulphate [SDS], 40% [v/v] glycerol, 0.01% [w/v] bromophenol blue,
1% [v/v] β-mercaptoethanol) and boiled for 5 minutes. Samples were then loaded into 15%
polyacrylamide resolving gels (15% [v/v] acrylamide/bisacrylamide [37.5:1] aqueous
solution, 0.25% [v/v] 1.5 M Tris-HCl pH 8.8, 0.1% [w/v] SDS, 0.1 % [w/v] ammonium
persulfate [APS], 0.15% [v/v] tetramethylethylenediamine [TEMED]) with 5%
polyacrylamide stacking gel (5 % [v/v] acrylamide/bisacrylamide [37.5:1] aqueous
solution, 25% [v/v] 0.5 M Tris-HCl pH 6.8, 1.3% [w/v] SDS, 0.1 % [w/v] APS, 0.2% [v/v]
TEMED) and run for 50 minutes at 200 V (Mini-PROTEAN System, Bio-Rad Laboratories
Inc.) using Tris-Glycine electrophoresis buffer (192 mM glycine, 25 mM Tris, 0.1% [w/v]
SDS, pH 8.3). Polyacrylamide gels were stained for 1 hour with staining solution (45%
[v/v] methanol, 10% [v/v] glacial acetic acid, 0.1% [w/v] Coomassie Brilliant Blue R-250
[Bio-Rad Laboratories Inc.) and immediately placed in destain solution (45% [v/v]
methanol, 10% [v/v] glacial acetic acid) several times until background staining was
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resolved. To estimatre protein molecular weight, samples were compared to Prestained
Broad Range P7708S Protein Marker (New England BioLabs Inc.) or BLUeye Protein
Ladder (GeneDireX Inc., Taiwan).
2.8.2

Western blot

To probe for specific proteins, contents from SDS-PAGE gel (prior to staining procedure)
were transferred onto polyvinylidine difluoride (PVDF) membrane (EMD Millipore). To
accomplish this, PVDF membrane was first incubated in 100% methanol for 5 minutes,
followed by immersion in Western blot transfer buffer (20% [v/v] methanol, 48 mM Tris
base, 39 mM glycine, 0.037% [w/v] SDS) for 5 minutes. The prepared PVDF membrane
and SDS-PAGE gel were then assembled together in a Mini Trans-Blot® Cell (Bio-Rad
Laboratories Inc.) with Western blot transfer buffer and electroblotted for 1 hour at 100 V
or overnight at 25 V with a cold block. The PVDF membrane was then blocked for 30
minutes with 5% (w/v) skim milk powder in Tris buffered saline (TBS; 100 mM Tris, 1.5
M sodium chloride, pH 7.5). Post-blocking, the membrane was incubated for 1 hour with
primary antibody (polyclonal rabbit anti-SAg; ProSci; see below; Table 6) diluted
1:10,000 in 1% (w/v) skim milk in TBS. To remove residual antibody, PVDF membrane
was washed three times in TBS with 0.01% (v/v) tween-20 (TBS-T) for 5 minutes per
wash. IRDye800-conjugated goat anti-rabbit (Rockland Inc.; Limerick, PA, USA)
secondary antibody was diluted 1:10,000 in 1% (w/v) skim milk powder in TBS and
incubated with the PVDF membrane for 1 hour, shielded from light at room temperature.
The membrane was washed three times with TBS-T as mentioned previously, and imaged
on a LI-COR® Odyssey Imaging System (LI-COR Biosciences; Lincoln, NE, USA).
Antibody generation
Purified SAg toxins in 150 mM sodium chloride (pH 7.5), were sent to ProSci Inc. (Poway,
CA, USA) for production of polyclonal rabbit anti-SAg antibodies. New Zealand White
rabbits were injected with 200 µg of SAg with complete Freund’s adjuvant at week 0, and
boosted with 100 µg SAg with incomplete Freund’s adjuvant at weeks 2, 4 and 6. Serum
was collected at week 0, 5 and 7 with terminal bleed taken at week 8. Serum samples were
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Table 6: Antibodies and dyes used in this study
Target
Fluorophore/Conjugate
Passive Immunization/Western Blot
SpeA
N/A
SpeC
N/A
Anti-Rabbit IgG
IRDye800
T cell Depletion
CD4
N/A
CD8
N/A
KLH
N/A
Vβ4
N/A
Vβ8
N/A
Flow Cytometry – Mouse
CD3ε
APC
CD4
APC-eFluor 780
CD8a
PE
CD25
PE
TCR Vβ3
FITC
TCR Vβ4
FITC
TCR Vβ8.1/8.2
FITC
Flow Cytometry – Human
7-AAD
N/A
CD3
APC
CD4
BV 711
CD8
Alexa Fluor 700
CD25
PE
PD-1
BV 421
ELISA – Antibody Titre
Anti-Mouse IgG
HRP
Anti-Mouse IgM HRP

Clone

Source

Polyclonal (Rabbit)
Polyclonal (Rabbit)
Polyclonal (Donkey)

ProSci
ProSci
Rockland

GK1.5
YTS169.4
LTF-2
KT4
F23.1

BioXCell
BioXCell
BioXCell
BioXCell
BioXCell

145-2C11
GK1.5
53-6.7
7D4
KJ25
KT4
KJ16

eBioscience
eBioscience
eBioscience
BD Pharmingen
BD Pharmingen
BD Pharmingen
eBioscience

N/A
UCHT1
RPA-T4
RPA-T8
M-A251
EH12.2H7

eBioscience
BD Pharmingen
BioLegend
BD Pharmingen
BD Pharmingen
BioLegend

Polyclonal (Goat)
Polyclonal (Goat)

Sigma-Aldrich
Rockland
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assessed for anti-SAg antibody titre using enzyme-linked immunosorbent assay (ELISA;
see below), aliquoted and stored at -80°C until use.
In vivo experiments
2.10.1

Mice

Other than size, there were no gender differences (bacterial load, response to SAgs, etc.)
between male and female mice between any of the strains used in this study. It was
therefore determined that when possible equal numbers of male and female mice would be
used in each group, however, this was not a requirement for experimentation.
Housing and breeding
Mice were bred and housed in the West Valley Barrier Facility (Western University,
London, ON, Canada) and moved to the Animal Holding Facility on the sixth floor of the
Dental Sciences Building (Western University, London, ON, Canada) for undertaking of
experiments. In both facilities mice were housed under specific pathogen-free conditions
with food and water ad libitum.
Strains utilized
A list of all mice used in this study can be found in Table 7. C57Bl/6 mice expressing the
transgenic major histocompatibility complex (MHC) class II human leukocyte antigen
(HLA)-DR4 and DQ8 were obtained from the Kotb Laboratory and have been previously
described [348,369,457]. Mice expressing the DQ8 gene alone were outbred from HLADR4/DQ8 by selecting for mice containing only the HLA-DQ8 allele. Conventional
C57Bl/6 mice were obtained from The Jackson Laboratory.
2.10.2

Passive immunization

HLA-DQ8 mice 12-14 weeks of age were injected in the intraperitoneal cavity with 500
µL of rabbit anti-SAg serum -24 and -2 hours prior to nasopharyngeal infection with S.
pyogenes (see below).
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Table 7. Mouse strains used in this study
Strain
C57Bl/6

Characteristic
Inbred black mouse

Source
Jackson Laboratories (Bar
Harbor, ME, USA)

HLA-DR4/DQ8

C57Bl/6 mice null for [369]; McCormick
endogenous H2b MHC breeding colony
class II and transgenic for
human HLA-DR4 and
HLA-DQ8

HLA-DQ8

C57Bl/6 mice null for McCormick lab breeding
endogenous H2b MHC colony
class II and transgenic for
human HLA-DQ8

lab
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2.10.3

Vaccination experiments

Vaccination of 6-8 week old HLA-DR4/DQ8 mice has been previously described [377].
Briefly, mice received 1 µg (unless otherwise stated) SAg or toxoid in 200 µL (100 µL 150
mM sodium chloride, pH 7.5; 100 µL Imject™ Alum Adjuvant [Thermo Fisher Scientific])
subcutaneously under isoflurane anesthetic. Control mice received only saline solution and
adjuvant. Injections were received on day 0, 14 and 28, and mice were bled via saphenous
vein on day 42 to assess antibody titre (see below). Mice were weighed on day 0 prior to
injection, day 7, 21 and 42 to determine if SAg injection had any effect on weight gain. To
assess T cell responsiveness post-vaccination, spleens were removed on day 43 and
subjected to an activation assay (see below). Where applicable, nasopharyngeal infection
occurred on day 43 (see below).
2.10.4

T cell depletion

Murine depletion of T cells has been previously described [458]. In brief, HLA-DQ8 mice
received 300 µg of anti-CD4 (GK1.5; BioXCell; West Lebanon, NH, USA), anti-CD8
(YTS169.4; BioXCell) or isotype control (LTF-2; BioXCell) alone or in combination in
500 µL of PBS, pH 7.5. Injections were received on day -7, -6 and -1. On day 0, mice were
either sacrificed for lymph node procurement and flow cytometric analysis or streptococcal
infection (see below).
2.10.5

Murine nasopharyngeal infection

Mice were given 2 mg ml-1 neomycin sulphate ad libitum in their drinking water two days
prior to infection to reduce the nasal microbiota. Regardless of infecting bacteria, mice
were sacrificed 48 hours post infection and cNT, blood, spleen, liver, kidneys, lungs and
heart were removed for bacterial enumeration and cytokine analysis where indicated.
S. pyogenes preparation and inoculation
Preparation of S. pyogenes MGAS8232 for inoculation has been previously described
[377,459]. In brief, S. pyogenes MGAS8232 was grown from freezer stock (see above) in
THY broth statically at 37°C and subcultured 1:100 for two days. On the third day, the
bacteria was subcultured (7%) into 100 mL of pre-warmed THY broth and grown until an
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OD600 of ~0.3. Using the equation generated from the bacterial growth curve (see above),
the appropriate volume containing 1 × 109 CFU was centrifuged at 2,000 × g for 7 minutes
and the supernatant was removed. The bacterial pellet was transferred to a new container
and spun at 21,000 × g for one minute. The residual supernatant was removed and the pellet
was resuspended in 1 mL Hanks’ Balanced Saline Solution (HBSS; Wisent Bioproducts
Inc.; Saint-Bruno, QU, Canada) and spun as above. The supernatant was again removed
and the pellet was reconstituted in 150 µL HBSS for murine inoculation. One dose was
serially diluted and plated to determine the concentration of bacterial inoculum. Mice from
one of the above mentioned experimental methodologies were then anesthetized using

Pr

FORANE (isoflurane, USP; Baxter Corporation; Mississauga, ON, Canada) and 7.5 µL of
bacterial inoculum was administered to each nostril. The mice were then allowed to recover
from the anesthetic and monitored for the duration of the experiment. Inoculation with S.
pyogenes SF370 was completed as above with the following modification: after being
grown from the freezer stock, the bacteria were directly subcultured (7% v/v) into 100 mL
pre-warmed THY media without two days of subculturing.
S. pneumoniae preparation and inoculation
Nasal inoculation of S. pneumoniae was prepared similarly to Puchta el al. [460]. Briefly,
S. pneumoniae was grown from freezer stock in 10 mL TSB at 37°C with 5% CO2
overnight. The overnight growth was subcultured (7%) in 100 mL TSB and grown as above
until an OD600 ~0.3 was reached. Using the generated equation (see above), the appropriate
volume containing 1 × 108 CFU was spun at 15,000 × g for 1 minute. The supernatant was
removed and the pellet was resuspended in 100 µL of PBS, pH 7.5. One dose was serially
diluted and plated to determine the concentration of bacterial inoculum. T cell depleted or
isotype control treated mice were then anesthetized using

Pr

FORANE (isoflurane, USP;

Baxter Corporation; Mississauga, ON, Canada) and 5 µL of bacterial inoculum was
administered to each nostril. The mice were then allowed to recover from the anesthetic
and monitored for the duration of the experiment.
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Antibody titre analysis
Antibody titres were determined using ELISA. Wells of a Corning Costar 9018 (Corning;
Corning, NY, USA) 96-well high-bind plate were coated with 100 µL of indicated SAg
(10 µg mL-1) in coating carbonate buffer (affymetrix eBioscience; Thermo Fischer
Scientific) and was left at room temperature overnight in a humidified chamber. Plates
were subsequently washed twice with distilled water. Plates were then blocked with PBS
containing 1% (w/v) bovine serum albumin (BSA) and 0.05% (v/v) tween-20 for 2 hours
at room temperature and washed as above. Mouse serum samples were diluted starting at
1:100 in PBS containing 0.1% (w/v) BSA and 0.05% (v/v) tween-20 to a final volume of
100 µL per well followed by two-fold serial dilutions down the plate until a final dilution
of 1:204,800 was reached. Plates were incubated at room temperature for 2 hours and
washed three time in wash buffer (PBS containing 0.05% v/v tween-20) followed by three
washes with distilled water. Goat anti-mouse horseradish peroxidase (HRP)-conjugated
secondary antibody (Sigma-Aldrich) was added at a dilution of 1:10,000 to a final volume
of 100 µL/well and incubated at room temperature for 2 hours. Plates were washed 5 times
as above and developed by adding 100 µL/well of 3, 3′, 5, 5′ Tetramethybenzidine (TMB;
BD Biosciences) for 15 minutes. Colour change was halted by addition of 50 µL of 1 M
H2SO4 and plates were read at OD450 with OD570 subtraction. Positive antibody titre was
calculated as the reciprocal of the lowest serum dilution with readings four-fold above
background.
Ex vivo experiments
2.12.1

Cell preparation
Murine splenocytes

Spleens were procured from euthanized mice and immediately stored on ice in 5 mL of
HBSS. Spleens were pressed through a sterile 0.2 µm nylon mesh filter and the single-cell
suspension was centrifuged at 450 × g for 5 minutes. The supernatant was removed and the
pellet was loosened via racking. Red blood cells were lysed by addition of 1 mL ammonium
chloride potassium (ACK) lysing buffer (Thermofisher Scientific Inc.) for 30 seconds. To
stop the lysis reaction, 10 mL of PBS, pH 7.5 was added and the cells were spun as above.
Cells were resuspended in 7 mL PBS buffer and sieved through nylon mesh filter as above
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to remove cell debris. The filter was washed with an additional 7 mL PBS to ensure
collection of all living cells. The collected sample was spun as above, the supernatant was
discarded, and the pellet was racked, and then resuspended in 4 mL of complete RPMI
(cRPMI) media (RPMI-1640 [Life Technologies Inc.] supplemented with 0.1 mM minimal
essential medium non-essential amino acids [Life Technologies Inc.], 10% [v/v] heatinactivated fetal bovine serum [Sigma-Aldrich], 100 units mL-1 penicillin [Life
Technologies Inc.], 100 µg mL-1 streptomycin [Life Technologies Inc.], 1 mM sodium
pyruvate [Life Technologies Inc.], and 2 mM L-glutamine [Life Technologies Inc.]). Live
cells were counted using Trypan Blue (Life Technologies Inc.) exclusion and resuspended
to a concentration as required for the indicated assay.
Murine lymph nodes
Cervical lymph nodes were procured from anaesthetized mice and immediately
homogenized in 5 mL of ice-cold PBS, pH 7.5 using a glass homogenizer. Cells were
processed as above, however, no ACK lysing buffer was required.
Human peripheral blood mononuclear cells
Blood was obtained from healthy donors with ethics approval (Appendix 1). Whole blood
was mixed with pre-warmed RPMI-1640 (Life Technologies Inc.) in a 1:1 ratio. The blood
mixture was added to room-temperature Ficoll (GE Healthcare; Fairfield, CT, USA) in a
1:2 (blood : Ficoll) ratio. Tubes were spun for 30 minutes at 913 × g and stopping was done
without the aid of a break. The PBMC layer was carefully transferred to a new tube and
washed with RPMI (Life Technologies Inc.) three times. With each wash, spin intensity
decreased (514, 329, and 185 × g, respectively with break). Cells were resuspended in
cRPMI and live cells were counted using Trypan Blue exclusion and diluted to the
appropriate concentration as required for the indicated assay.
2.12.2

T cell activation assay

Cells were seeded at 2 × 105 cells per well in a 96-well plate. SAgs at indicated
concentrations were added, and cells were incubated at 37°C with 5% CO2 for 18 hours.
Cells were spun, and supernatant was removed and stored at -20°C until further
experimentation. To assess activation, IL-2 was measured using ELISA (mouse IL-2
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ELISA Ready-Set-Go! Kit [eBioscience Inc.] or human IL-2 ELISA Kit [BD Biosciences
Inc.]) according to the manufacturer’s instructions. Briefly, Corning Costar 9018 (Corning)
96-well high-bind plates were coated overnight at 4°C with appropriate capture antibody
in supplied carbonate capture buffer. Plates were washed twice with wash buffer (PBS with
0.05% [v/v] tween-20) and blocked for 2 hours at room temperature with assay diluent.
Plates were washed as above and supernatant from stimulated cells was added (murine
splenocyte supernatant added neat; human PBMC supernatant diluted 1:4 with assay
diluent) and incubated at room temperature for one hour. Plates were washed as above
three times, and detection cocktail was added (primary antibody-biotin and avidin-horse
radish peroxidase conjugates were incubated together in assay diluent for 30 minutes prior
to addition to 96-well plate) for one hour. Plates were washed five times as above, and
supplied TMB was added for 15 minutes prior to colour change stoppage by addition of 1
M H2SO4. All plates were read on a Synergy H4 plate reader (BioTek Instruments Inc.) by
assessing absorbance at OD450 and subtracting OD570. Concentrations were determined by
comparing supernatant concentrations to supplied standards, and limit of detection was
3.125 ng mL-1 for murine IL-2 and 7.8 ng mL-1 for human IL-2.
2.12.3

Flow cytometry

Isolated cells were aliquoted at a concentration of 1 × 106 cells per tube, centrifuged at 450
× g for 5 minutes, supernatant was removed, pellet was resuspended by racking and washed
in 2 mL of FACS wash buffer (PBS supplemented with 2% [v/v] fetal bovine serum and
0.01% [w/v] sodium azide). Cells were spun again as above, supernatant was removed, and
cells were resuspended as above. Cells were incubated with appropriate concentrations of
fluorophore-conjugated antibodies or cell viability dyes according to the manufacturer’s
instructions for 30 minutes at 4°C or on ice protected from light. In low-light conditions,
samples were washed three times as above, resuspended in 400 µL of FACS wash buffer,
and read on an LSR II Flow Cytometer (BD Biosciences Inc.).
2.12.4

T cell proliferation assay

T cell proliferation was measured from human PBMCs using the CellTrace™
carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit (Thermo Fisher
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Scientific Inc.) as per the manufacturer’s instructions. Briefly, 10 × 106 cells were
resuspended in 37°C pre-warmed RPMI-1640 (Life Technologies Inc.) and a 5 mM
CellTrace™ CFSE stock solution was created by diluting the stock solution with dimethyl
sulfoxide (DMSO). The CFSE solution is added to the cells to generate a final
concentration of 10 µM and cells are incubated in a water bath protected from light at 37°C
for 10 minutes with gentle mixing at 5 minutes. Cell labelling was stopped by addition of
30 mL of 4°C cRPMI, and the cell mixture was incubated on ice for 5 minutes. The cells
were spun at 403 × g for 10 minutes and resuspended in cRPMI. Cells were aliquoted at 8
× 105 cells per tube, and stimulated with varying concentrations of SAg or untreated
control. Polymixin B was then added to a final concentration of 2 µg mL-1 and cells were
incubated at 37°C with 5% CO2 for 5 days before flow cytometry analysis using a LSR II
Flow Cytometer (BD Biosciences Inc.).
Multiplex cytokine array
Cytokine and chemokine concentrations were determined from the cNT of HLA-DQ8 mice
treated with LTF-2 (isotype control), GK1.5 (anti-mouse CD4), YT169.4 (anti-mouse
CD8) or a combination of GK1.5 and YTS169.4 and infected with either S. pyogenes
MGAS8232 or S. pneumoniae P1121. S. pyogenes infected HLA-DR4/DQ8 mice from
wild-type SpeA and SEB vaccination groups, and a sham group, were also assessed.
Uninfected HLA-DR4/DQ8 cNT homogenates were tested as a background control.
Mutiplex cytokine array (Mouse Cytokine/Chemokine Array 31-Plex) was performed by
Eve Technologies (Calgary, AB, Canada) and heat maps were generated using Matrix2png
[461]. The data is shown as average cytokine response from 3-4 mice per group normalized
to the highest concentration as 100% between all groups. Statistical analysis was completed
by the appropriate test within groups (Appendix 4).
Statistical analysis
Data was analyzed using unpaired Student’s t-test, one-way analysis of variance (ANOVA)
with Dunnett’s multiple comparisons post-hoc test or two-way ANOVA with Tukey’s or
Dunnett’s multiple comparison post-hoc test, as indicated. A value of P less than 0.05 was
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determined to be statistically significant and all analyses were completed using Prism
software (GraphPad Software, Inc.; La Jolla, CA, USA).
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Chapter 3: Results
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Results
Generation and purification of wild-type and SpeA toxoid superantigens
Wild-type SAg expression constructs, and select mutant toxoid constructs, were previously
designed by members of the McCormick laboratory (Table 4). Constructs were generated
in either the expression construct pET28a or pET41a, with either a TEV protease or
thrombin cleavage site between the His6-Tag and the SAg gene (Figure 3A). Proteins were
expressed by IPTG induction in E. coli BL21 (DE3), and purified from cell lysate using
two-step nickel-affinity column chromatography (Figure 3B-D). For all SpeA mutant
toxoids (except SpeAHEXA) that had not been previously generated, megaprimer PCR
amplification was used with the appropriate primers (Table 5) (Figure 4A). SpeAHEXA was
previously generated and published [437] without a TEV cleavage site between the His6Tag and the SAg gene. This construct was generated by amplifying the SpeAHEXA gene
from the original construct using primers that added the nucleic acid sequence for a His6Tag, TEV protease cleave site with appropriate restriction enzyme sites for cloning into the
pET28a expression vector (Table 5; Figure 4B).
To supplement the previously designed MHC II binding site SpeA toxoid (SpeAY100A)
[454], numerous other toxoids were generated using megaprimer PCR (Figure 4A)
including: a TCR-binding interface toxoid (SpeAN20A); a toxoid containing both N20A and
Y100A amino acid substitutions (SpeAN20A/Y100A); a further attenuate MHC II toxoid which
combined the Y100A substitution with two additional substitutions at this interface (L41A
and L42A; designated SpeATRI); as well as a toxoid that contained all the aforementioned
substitutions (N20A/L41A/L42A/Y100A; designated SpeATETRA). The choice of the
amino acid mutations were based upon previously published literature describing the
attenuation of SpeA by the addition of these mutations [437,439,462]. SAg structures and
relevant mutations were observed visually using PyMOL (The PyMOL Molecular
Graphics System, Version 1.8 Schrödinger, LLC.). To generate the ribbon diagram, SEB
in complex with TCR and MHC class II (4C56) [215] was used as a scaffold. The SpeA
(1FNU) [203], HLA-DQ8 (1JK8) [463] and murine TCR vβ8 (1SBB) [220] constructs
were superimposed onto the corresponding structures from the SEB ternary complex
(Figure 5).
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Figure 4. Polymerase chain methodology for the generation of SpeA toxoids.
A. Mutant SpeA derivatives were generated by PCR amplification from speA housed in the
pET28a expression plasmid. Forward and reverse primers spanned the area of interest and
contained the appropriate nucleic acid changes to result in desired amino acid substitutions,
with flanking upstream and downstream regions left complementary to the wild-type gene.
Amplification of the construct using these primers resulted in a product containing the
desired substitution. Restriction enzyme digestion with DpnI eradicated the parent plasmid
and left only the desired toxoid construct, which could then be directly transformed into
chemically-competent Escherichia coli and circularized by host DNA repair mechanisms.
B. SpeAHEXA was provided by a collaborator and has been previously described [437]. The
plasmid housing the speAHEXA gene did not have the desired purification or cleavage tags,
so the gene was moved to a new expression plasmid using megaprimer PCR amplification.
A forward primer containing the desired restriction enzyme cut site, 6x His-Tag and
tobacco etch virus (TEV) protease cleavage site as well as 5′ sequence overlap to speAHEXA
were used in combination with a reverse primer that had a second restriction enzyme cute
site and 3′ overlap. Amplified gene product and empty pET28a expression plasmid were
digested with indicated restriction enzymes, ligated together and transformed into desired
chemically-competent E. coli strains. All transformants were selected for on media
containing specific antibiotics and toxoid product sequences were confirmed using DNA
sequencing.
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Figure 5. Visualization of SpeA toxoid amino acid substitutions.
A. Ribbon diagram cartoon of the SpeA crystal structure (grey) (1FNU) [203] in complex
with murine TCR Vβ8 (yellow) (1SBB) [220] (α-chain, blue) and MHC class II HLA-DQ8
(α-chain, red; β-chain, green) (1JK8) [463] was generated using the published
TCR/SEB/MHCII trimolecular complex (4C56) [215] as a scaffold. B. and C. Inset box
shows an up-close view of the SpeA immune complex interaction interface with
highlighted

amino

acids

(cyan)

(Q19H/N20D/L41A/L42A/D45N/C98S)

substituted
and

in
(C)

(B)

SpeAHEXA
SpeATETRA

(N20A/L41A/L42A/Y100A). Images were generated with PyMOL (The PyMOL
Molecular Graphics System, Version 1.8 Schrödinger, LLC.).
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To generate purified SAg protein, cell lysate from induced bacterial strains that contained
the desired SAg expression plasmids was applied to charged nickel resin column. His6tagged proteins were eluted from the column with increasing concentration of imidazole
(Figure 3A). SDS-PAGE gels were used to determine fractions containing the desired
protein which were subsequently dialyzed to remove imidazole and the His6-Tag was
removed by addition of either autoinactivation-resistant His7::TEV [456] or thrombin
depending on the construct (Table 4). Samples were again passed over a charged nickel
column to removed purification tags and HIS7::TEV (Figure 3C). SAgs were isolated in
wash or low imidazole concentrations and confirmed by size comparison on an SDS-PAGE
(approximately 25kDa). Pure samples were dialyzed into a saline solution for future
experimentation (Figure 3D).
Evaluation of superantigen function on immune cells
3.2.1

Human PBMC proliferation, activation and anergy induced by wild-type
superantigens

The ability of purified wild-type SAgs to activate, cause proliferation and induce anergy in
human PBMCs was assessed using flow cytometry (Figure 6). Cells were isolated from a
healthy human donor and incubated with increasing concentrations of SAgs for 5 days.
Proliferation was based on dilution of CFSE within dividing cells (Figure 6B), activation
was based upon expression of CD25 (Figure 6C) and anergy was based upon expression
of PD-1 (Figure 6D). All SAgs were able to activate, proliferate and induce anergy in both
CD4+ and CD8+ cells, however, this donor was a low responder to SpeA and SSA.
A second marker of activation – IL-2 – was also measured. Human PBMCs from the same
donor were incubated with increasing concentrations of SAgs for 18 hours and IL-2 from
culture supernatants were measured. Similar to the results above, it was demonstrated that
all SAgs could activate human PBMCs, and it was noted that this donor was a low
responder to SpeA and SSA (Figure 6E).
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Figure 6. Activation of human T cells by recombinant streptococcal superantigens.
Human peripheral blood mononuclear cells (PBMCs) were isolated from a healthy donor
via Ficoll gradient centrifugation and stimulated with increasing concentrations of each
streptococcal SAgs to assess their ability to proliferate, activate and induce markers of
anergy in cells. A. Purified streptococcal SAgs were visualized using 12% SDS-PAGE. B
– D. Human PBMCs were incubated with the indicated concentrations of SAg for five
days. Cells were then analyzed by flow cytometry to assess (B) proliferation (CFSELow),
(C) activation (CD25+) and (D) anergy (PD-1+) of CD3+ CD4+ or CD3+ CD8+ cells. Data
represent singular values. (E) PBMCs were also incubated with indicated concentrations
of SAg for 18 hours to assess activation based on supernatant IL-2 concentration as
determined by ELISA. Data represent the mean of triplicate values. SAgs are colour-coded
as indicated in the legend.
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3.2.2

Evaluation of activation potential by wild-type superantigens on murine
splenocytes

The ability of SAgs to activate conventional C57Bl/6 and transgenic HLA-DR4/DQ8 mice
was evaluated. Splenocytes from both mouse strains were stimulated with increasing
concentrations of SAgs and culture supernatants were analyzed for IL-2 using ELISA. In
contrast to humans, conventional C57Bl/6 mice were only stimulated by SpeH, SpeI and
to a lesser extent SpeL, SpeM and SmeZ (Figure 7A). HLA-DR4/DQ8 transgenic mice
were slightly more sensitive to the above mentioned SAgs, but were also stimulated by
SpeA (Figure 7B). In comparison to human cells (Figure 6), the murine cells were
stimulated to a much lower magnitude comparing overall concentrations of IL-2 in culture
supernatant.
Confirmation of MHC II dependence during S. pyogenes infection
Previous work from our laboratory has demonstrated the requirement for murine
expression of human MHC II for efficient nasopharyngeal infection by S. pyogenes [449].
To confirm this finding, conventional C57Bl/6, HLA-DQ8 or HLA-DR4/DQ8 mice were
infected with S. pyogenes MGAS8232. As previously shown, conventional C57Bl/6 mice
were poorly infected by this strain of Group A Streptococcus, whereas mice expressing
HLA-DQ8 (or -DR4/DQ8) had a significantly higher bacterial load at 48 hours (Figure
8A).
A second strain of S. pyogenes was tested for this MHC II dependence phenotype. S.
pyogenes SF370 was inoculated into C57Bl/6 and HLA-DQ8 mice and nasopharyngeal
bacterial load was assessed. Conventional C57Bl/6 mice were shown to harbor
significantly less bacteria than their HLA-DQ8-exressing counterparts, confirming human
MHC II dependence during infection for this strain of Group A Streptococcus (Figure 8B).
In vivo detection of superantigen expression
Our laboratory has elucidated the importance of the SAg SpeA for nasopharyngeal
infection by S. pyogenes MGAS8232 of HLA-DR4/DQ8 transgenic mice [449]. To
determine if SpeA was expressed and could be detected by subsequent lymphocyte
activation in vivo, mice were infected with either wild-type or S. pyogenes MGAS8232
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Figure 7. Conventional and transgenic mouse T cell responses to streptococcal
superantigens.
Splenocytes from (A) conventional C57Bl/6 or (B) transgenic mice which lack endogenous
murine MHC class II but express HLA-DR4 and HLA-DQ8 were stimulated with indicated
concentrations of streptococcal SAgs for 18 hours. Culture supernatants were then
analyzed for IL-2 using ELISA as a marker of T cell activation. Data represent the mean ±
SEM of triplicate values from a single mouse. SAgs are colour-coded as indicated in the
legend.
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Figure 8. Efficient nasopharyngeal infection by S. pyogenes requires transgenic
expression of human MHC class II molecules.
Conventional C57Bl/6 or transgenic mice expressing the indicated human leukocyte
antigen MHC class II molecules were intranasally infected with 108 CFU of either (A) S.
pyogenes MGAS8232 or (B) S. pyogenes SF370 for 48 hours. Data points represent CFU
from the cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted
line indicates the theoretical limit of detection. Significance determined by (A) one-way
ANOVA with Tukey’s post-hoc test (***, P < 0.001) or (B) Student’s t test (*, P < 0.05).
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ΔspeA and cervical lymph nodes were removed at 48 hours post-infection. SpeA-targeted
lymphocytes were stained for activation markers and were compared to a non-targeted
internal control. Using flow cytometry, live lymphocytes were gated first using forward
and side scatter. Cells expressing CD3+ surface antigen were then gated. Expression of the
activation marker CD25+ on SpeA-targeted T cell subset expressing the TCR Vβ8 chain
was compared this to an internal control (TCR Vβ3 expressing T cells) (Figure 9A). It was
demonstrated that between the two strains, there was no significant difference in the
percentage of CD3+ TCR Vβ+ subsets (Figure 9B), however, there was a significant
difference in the percentage of TCR Vβ8+ CD25+ T cells (targeted by SpeA) but not the
non-SpeA targeted subset (TCR Vβ3) (Figure 9C). This data was also supplemented with
cNT counts and which again demonstrated the importance of SpeA in our nasopharyngeal
infection model (Figure 9D).
Anti-superantigen passive immunization protects mice from S. pyogenes infection
To assess whether anti-SAg antibodies could be protective against S. pyogenes MGAS8232
nasopharyngeal infection, a passive immunization experiment was designed. HLA-DQ8
transgenic mice were administered hyper-immune serum from previously immunized
rabbits containing antibodies to either SpeA or control serum containing anti-SpeC
antibodies, as deletion of speC from S. pyogenes MGAS8232 had no effect on the infection
phenotype [377]. After passive transfer, mice were infected with S. pyogenes MGAS8232
and sacrificed 48 hours later (Figure 10A). Murine cNT was removed to assess
nasopharyngeal bacterial burden and blood was drawn to examine antibody titres. Mice
treated with anti-SpeA immune serum had significantly reduced bacterial load compared
to control serum (Figure 10B). In addition, Western blot analysis demonstrated that the
rabbit serum was specific for each SAg, and that the serum was not cross-reactive between
SpeA and SpeC (Figure 10 C). As expected, protected mice had significantly higher antiSpeA antibodies present in their blood, and the lack of cross-reactivity was confirmed by
ELISA (Figure 10 D and E). These results indicate that anti-SAg antibodies can be
protective in a S. pyogenes nasopharyngeal infection model.
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Figure 9. Detection of superantigen-dependent Vβ-specific T cell activation in vivo.
Flow cytometric analysis of HLA-DR4/DQ8 cervical lymph node cells and cNT bacterial
counts 48 hours post-infection with wild-type S. pyogenes MGAS8232 or MGAS823
ΔSpeA (n ≥ 4 for each group). A. Cells were first gated on live lymphocytes using FSC
and SSC followed by gating on CD3+ cells and either Vβ3+ CD25+ or Vβ8+ CD25+ cells.
B. Percentages of Vβ3+ and V8+ subsets were compared between groups. C. Percentages
of Vβ+ CD25+ cells were compared between groups. D. Data points represent CFU from
the cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted line
indicates the theoretical limit of detection. Significance determined by Student’s t test (**,
P < 0.01; ***, P < 0.001).
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Figure 10. Passive immunization with hyper-immune anti-SpeA rabbit serum reduces
the burden of S. pyogenes MGAS8232 in the nasopharynx.
A. Passive immunization schedule. B. Nasal challenge of HLA-DQ8 transgenic mice with
108 CFU S. pyogenes MGAS8232 after passive immunization with rabbit anti-SpeA or
anti-SpeC serum. Data points represent CFU from the cNT of individual mice at 48 hours.
Horizontal bars represent the mean. The horizontal dotted line indicates the theoretical limit
of detection. C. Recombinant SAg (15% SDS-PAGE; top panel) and Western blot (bottom
two panels). D and E. Serum IgG antibody titres determined using ELISA from HLA-DQ8
mice (n ≥ 4) passively immunized with indicated treatment. Plates were coated with 100
µL of 10 µg mL-1 SpeA (D) or SpeC (E). Bars represent the mean ± SEM. Colours
correspond throughout the figure as follows: α-SpeA, red; α-SpeC, yellow. Significance
determined by unpaired Student’s t test (*, P < 0.05; **, P < 0.01).
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Evaluation of differing SpeA concentrations for vaccine dosage
Since it was previously determined that SpeA was required for efficient murine
nasopharyngeal infection by S. pyogenes MGAS8232 and that its activating potential could
be detected in vivo, we decided to target this SAg for our vaccination studies. To determine
an optimal concentration for SAg vaccination, three groups of HLA-DR4/DQ8 transgenic
mice were administered different concentrations (100 ng, 1 µg or 10 µg) of SpeA with
alum adjuvant. Mice received subcutaneous injections under isoflurane anesthetic on day
0, 14 and 28 with blood being drawn via saphenous vein on day 42 to assess antibody titres
(Figure 11A). Weight was also monitored on day 0 prior to the first injection, and on day
7, 21 and 42 to determine if there was a detrimental effect on weight gain by wild-type
SpeA injections. Mice were then infected with S. pyogenes MGAS8232, and the bacterial
burden was assessed. The only vaccination dose to show a significant protective effect was
1 µg although there were trends at both the low and the high doses (Figure 11B).
Interestingly, there was no statistical difference in anti-SpeA IgG titres either, however, an
increased trend was noted in the 10 µg treatment group (Figure 11C). Consistent with the
non-invasive nature of the model [449], S. pyogenes was below the limit of detection in the
blood, spleen, kidneys, liver and heart (Figure 12A-E). Control lungs had two cases of S.
pyogenes detection above the limit of detection, but these counts were not statistically
different compared to any other treatment group (Figure 12F). All treatment group weights
increased during the vaccine regimen, and there was no difference between groups (Figure
12G).
Wild-type superantigen vaccination protection stems from reduced and
unresponsive T cell subsets
After it was concluded that 1 µg of SpeA was the optimal tested dose that reduced murine
nasopharyngeal bacterial burden compared to our control group, this concentration was
used for the remainder of our vaccine experimentation. The observation that significant
antibody titres were not present in our protective SpeA dose (Figure 11C) made us
consider an alternative explanation for this protective phenotype. SAgs are known to
interact with both T cells and antigen presenting cells; however, their impact on T cells has
been more rigorously studied. Thus, we sought to examine the effects of our wild-type
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Figure 11. Assessing effective dose of SpeA superantigen vaccination.
A. Superantigen vaccination protocol. B. HLA-DR4/DQ8 transgenic mice were vaccinated
with the SpeA at the indicated concentration and intranasally infected with 108 CFU S.
pyogenes MGAS8232 for 48 hours post-vaccination. Data points represent CFU from the
cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted line
indicates the theoretical limit of detection. C. Serum was collected 24 hours prior to
infection and used to assess antibody titre using ELISA (n ≥ 4). Data represented as the
mean ± SEM. Significance determined by one-way ANOVA with Dunnett’s post-hoc test
(*, P < 0.05).

90

91

Figure 12. Nasopharyngeal infection by S. pyogenes MGAS8232 is not invasive and
vaccination with SpeA does not alter weight gain.
A – F. HLA-DR4/DQ8 transgenic mice were vaccinated three times over a 28-day period
and infected two weeks post-vaccination with 108 CFU of S. pyogenes MGAS8232. Mice
were sacrificed 48 hours post-infection and indicated organs were removed, homogenized
and plated to assess bacterial burden. Data points represent CFU indicated organs of
individual mice. Horizontal bars represent the mean. Horizontal dotted line indicates the
theoretical limit of detection. A one-way ANOVA with Dunnett’s post-hoc test was used
to evaluate significance. G. Mice (n ≥ 4) were weighed on indicated days to assess impact
of SAg vaccination. Data represented as the mean ± SEM. Significance was assessed using
a two-way ANOVA with Dunnett’s post-hoc test.
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SpeA vaccine treatment on Vβ8+ T cells known to be targeted by SpeA. Two additional
SAg controls were included in these analyses. Staphylococcal enterotoxin B (SEB) is a
SAg that is produced by S. aureus, and also primarily targets Vβ8+ T cells. SpeC is a
streptococcal SAg that is unable to activate murine T cells due to an inability to interact
with murine TCRs [464] and was thus used as a negative control. SEB and SpeC were
purified (Figure 13A) and their ability to stimulate transgenic HLA-DR4/DQ8 mouse
splenocytes was assessed. It was confirmed that SEB has similar stimulation potential to
SpeA, and SpeC had no stimulation potential at the highest concentration tested (Figure
13B).
Following the above mentioned vaccination protocol in our transgenic HLA-DR4/DQ8
mice, S. pyogenes MGAS8232 nasopharyngeal bacterial burden was assessed. Mice treated
with either SpeA or SEB wild-type SAgs had significantly reduced bacterial loads
compared to both control groups (Figure 13C). In order to exclude the possibility of
antibody-mediated protection, anti-SpeA IgG titres were assessed across all groups and it
was shown no treatment generated titres above our saline/alum adjuvant control (Figure
13D). Splenocytes from the above mentioned groups were analyzed by flow cytometry to
assess the impact of SAg vaccination on specific TCR Vβ subsets. CD3+ TCR Vβ8+ and
TCR Vβ3+ (internal control) T cells subsets were compared between groups. There was a
relative decrease of detectable TCR Vβ8+ T cells in SpeA and SEB treated mice compared
to control treated mice, but no difference in TCR Vβ3+ T cells (Figure 14A and B). T cell
responsiveness was also tested by SAg stimulation of vaccinated mouse splenocytes.
Splenocytes from control-, SpeA- and SEB-vaccinated mice were processed and restimulated with either TCR Vβ8+ targeting SAgs (SpeA and SEB) or streptococcal
mitogenic exotoxin Z (SmeZ), a SAg that targets TCR Vβ11+ T cells (an unaffected T cell
subset) that was used as an internal control. Mice treated with either TCR Vβ8+-targeting
SAg had an impaired ability to be stimulated by TCR Vβ8+-targeting SAgs compared to
control-treated mice (Figure 14C and D). All groups were able to be stimulated by TCR
Vβ11+-targeting SAg SmeZ; however, SpeA and SEB treated mice seemed to respond
better to this SAg (Figure 14E). This data suggests that wild-type SpeA- and SEBvaccinated mice had impaired TCR Vβ8+ T cells, but other subsets (i.e. Vβ11) remained
responsive. This impairment also correlated with in vivo protection from S. pyogenes
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Figure 13. Vaccination with wild-type TCR Vβ8-targeting superantigens is protective
against nasopharyngeal infection by S. pyogenes MGAS8232 but does not appear to
be antibody mediated.
A. Purified SAgs visualized using 12% SDS-PAGE. B. Activation assay measuring the
ability of purified SAgs to stimulate HLA-DR4/DQ8 murine splenocytes as determined by
IL-2 production. Data represented as the mean ± SEM of triplicate values from a single
mouse. C. HLA-DR4/DQ8 mice were vaccinated with either a saline control and adjuvant
or the indicated SAgs as previously described. Mice were intranasally infected with 10 8
CFU of S. pyogenes MGAS8232 and sacrificed 48 hours later. Data points represent CFU
from the cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted
line indicates the theoretical limit of detection. D. Serum was collected 24 hours prior to
infection and used to assess antibody titre using ELISA (n ≥ 4). SpeA cNT and serum IgG
levels are the same as those reported in Figure 11 for mice vaccinated with 1 µg of SpeA.
Colours correspond to: control, black; SpeA, red; SEB, blue and SpeC, yellow. Data
represented as the mean ± SEM. Significance determined by one-way ANOVA with
Dunnett’s post-hoc test (***, P < 0.001).
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Figure 14. SpeA- and SEB-vaccinated mice have impaired Vβ8+ T cells.
A and B. Flow cytometric analysis of splenocytes at day 43 post-SAg vaccination (n = 4
for each group). A. Representative flow plots for each treatment group stained for CD3
(APC) and either Vβ3 or Vβ8 (FITC). Staining of Vβ3 and Vβ8 are from the same mouse.
Each sample was first gated on lymphocyte population based on FSC and SSC before
gating on CD3+ Vβ+ population. B. Percentage of CD3+ Vβ3+ or CD3+ Vβ8+ T cell subset
for each treatment group (control, black; SpeA, red; SEB, blue). Data are shown as mean
± SEM. Significance determined by two-way ANOVA with Dunnett’s multiple
comparison post-hoc test (*, P < 0.05; ***, P < 0.001).C – E. HLA-DR4/DQ8 mouse
splenocyte IL-2 activation assay post vaccination with control (●), SpeA (▲) or SEB (▼)
(n = 3 for each group). Treated mouse splenocytes were stimulated with increasing
concentrations of SAgs targeting specific TCR Vβ subsets (C) SpeA, Vβ8; (D) SEB, Vβ8;
(E) SmeZ, Vβ11. Stimulation occurred for 18 hours and culture supernatants were analyzed
for IL-2 using ELISA as a readout for T cell activation. Data is shown as the mean ± SEM
of triplicate values from each mouse.
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nasopharyngeal infection indicating that wild-type vaccine protection likely stems from
rendering specific SAg-targeted T cell subsets unresponsive.
Superantigen toxoid vaccination can induce protective antibodies in vivo
3.8.1

Vaccination with SpeAY100A elicits a protective but bimodal phenotype

Discovery that passive immunization with anti-SAg antibodies could reduce S. pyogenes
bacterial load in a murine nasopharyngeal infection model prompted us to test whether
vaccination with SAgs could generate protective antibodies. However, vaccination with
wild-type SpeA did not generate significant anti-SAg antibodies (Figure 13D) whereas
protection from this vaccination procedure stemmed from rendering a specific T cell subset
unresponsiveness (Figure 14), indicating that an alternative approach must be taken to
generate protective anti-SAg antibodies. To assess whether attenuated SAgs would be able
to generate antibodies upon vaccination, a previously generated SpeA variant with a
mutated MHC II interface – SpeAY100A – [454] was used. It was first shown that SpeAY100A
had reduced capacity to activate HLA-DR4/DQ8 murine splenocytes (as determined
through IL-2 production) compared to its wild-type counterpart (Figure 15A). Next,
transgenic HLA-DR4/DQ8 mice vaccinated with SpeAY100A had significantly reduced
bacterial load in their nasopharynx when infected with S. pyogenes MGAS8232 (Figure
15B). Upon assessment of antibody titres, it was discovered that despite the protective
effects in mice, only a fraction (3/5) elicited a high anti-SpeA IgG antibody response
(Figure 15C). Flow cytometric analysis of SpeAY100A-vaccinated mouse splenocytes
indicated that there was no reduction of Vβ8+ T cells compared to control-vaccinated mice
(Figure 15D). However, we were able to show, using our previously described T cell
responsiveness assay (Figure 14C-E), that in circumstances where vaccination with
SpeAY100A resulted in minimal anti-SpeA antibodies production (Figure 16A), Vβ8+ T
cells were poorly responsive, similar to what was shown with wild-type SpeA-vaccinated
mice (Figure 16B and C). In contract, SpeAY100A-vaccinated mice that generated high antiSpeA antibody titres had more responsive Vβ8+ T cells similar to control-vaccinated mice
(Figure 16B and C). Both low and high anti-SpeA antibody producing mouse splenocytes
had similar responsiveness to the TCR Vβ11+-targeting SAg SmeZ (Figure 16D) which
was used as an internal control to indicate that irrelevant TCR Vβ subsets were not
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Figure 15. Vaccination with either SpeAY100A or SpeAHEXA does not yield consistent
antibody-mediated protection.
A. Activation assay measuring ability of wild-type or toxoid SAg to stimulate HLADR4/DQ8 murine splenocytes as determined by IL-2 production. Data represented as the
mean ± SEM of triplicate values from a single mouse. B. HLA-DR4/DQ8 mice were
vaccinated with either a saline control or the indicated SAg toxoid. Mice were intranasally
infected with 108 CFU of S. pyogenes MGAS8232 and sacrificed 48 hours later. Data
points represent CFU from the cNT of individual mice. Horizontal bars represent the mean.
Horizontal dotted line indicates limit of detection. C. Serum was collected 24 hours prior
to infection and used to assess IgG antibody titres using ELISA (n ≥ 5). Data represented
as the mean ± SEM. Significance determined by one-way ANOVA with Dunnett’s posthoc test (*, P < 0.05; **, P < 0.01). D. Flow cytometric analysis of splenocytes at day 43
post-SAg vaccination (n ≥ 3 for each group). Treatment groups were stained for CD3
(APC) and either Vβ3 or Vβ8 (FITC). Each sample was first gated on live lymphocyte
population based on FSC and SSC before gating on CD3+ Vβ+ population. Data represents
percentage of CD3+ Vβ3+ or CD3+ Vβ8+ T cell subset for each treatment group. Data are
shown as mean ± SEM. Control Vβ percentage data is replicated from Figure 14B.
Statistical significance was assessed by two-way ANOVA with Dunnett’s multiple
comparison post-hoc test.
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Figure 16. SpeAY100A vaccination elicits a bimodal antibody phenotype.
A. Two HLA-DR4/DQ8 mice were vaccinated with SpeAY100A and antibody titre against
wild-type SpeA was determined by ELISA. B – D. The SpeAY100A-vaccinated HLADR4/DQ8 mouse splenocytes were stimulated separately with increasing concentrations of
two TCR Vβ8+-targeting SAgs, SpeA (B) and SEB (C), and a TCR Vβ11+-targeting SAg,
SmeZ (D), as an internal control. Incubation occurred for 18 hours and IL-2 was measured
from splenocyte culture supernatants as a marker for T cell activation. For comparison
purposes, control (●) and SpeA (●) curves were added from Figure 14C-E. The SpeAY100Avaccinated mice with low antibody titre (■) and with high antibody titre (▲) were assessed
for their ability to respond to exogenous SAgs (n = 1 repeated in triplicate for each group).
Data is shown as the mean.
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impacted by the vaccination protocol. This data suggests that vaccination with SpeAY100A
can result in two protective phenotypes: a low anti-SpeA antibody titre with unresponsive
TCR Vβ8+ T cells that protects similarly to wild-type SpeA vaccination, or a high antiSpeA antibody titres where T cell subsets are responsive and protection is antibodymediated.
3.8.2

SpeAHEXA induces high antibody titres but is not consistently protective

Our previous finding that SpeAY100A was still able to impair T cell responsiveness led us to
attempt vaccination with a further attenuated SpeA variant. It was previously shown that a
SpeA toxoid with six amino acid substitutions – SpeAHEXA – was protective in a rabbit
model of STSS [437]. We sought to determine if vaccination with this molecule would be
protective in our streptococcal murine nasopharyngeal infection model. SpeAHEXA was
unable to activate HLA-DR4/DQ8 transgenic murine splenocytes at even the highest
concentration tested (Figure 15A). Upon vaccination, only 50% of mice had reduced
bacteria load in the cNT (Figure 15B), despite all mice having consistently high anti-SpeA
antibody titres (Figure 15C). Assessment of T cell subsets using flow cytometry revealed
no differences in Vβ3+ or Vβ8+ T cell subsets compared to control-vaccinated mice (Figure
15D). This data demonstrates that the six amino acid substitutions of SpeAHEXA render it
unable to activate T cells and consistently generate high anti-SpeA antibody titres in vivo;
however, the antibodies generated were not reliably protective in our model of S. pyogenes
nasopharyngeal infection.
3.8.3

SpeATRI generates high antibody titres and is consistently protective

Due to the bimodal protection phenotype of SpeAY100A and the ~50% efficacy of SpeAHEXA
when used as a vaccine, a minimalistic approach was taken to generating an inactive SpeA
toxoid that contained as few amino acid substitutions as possible and provided consistent
protection and high antibody titres. Previous data has shown that the asparagine at position
20 is crucial for SpeA interacting with the TCR [437,462], and the leucine residues at
positions 41 and 42 have been previously shown to be important for interaction with MHC
II [437,439]. These residues were thus mutated to alanine using primer-based site-directed
mutagenesis both separately and in tandem to generate four new mutants. SpeAN20A,
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SpeAN20A/Y100A,

SpeATRI

(L41A/L42A/Y100A)

and

SpeATETRA

(N20A/L41A/L42A/Y100A) each were shown to have drastically reduced capacity to
activate murine splenocytes compared to wild-type SpeA (Figure 17A). Each of these
mutants was then tested in our vaccination regimen to assess protection from S. pyogenes
nasopharyngeal challenge (Figure 17B) and antibody titres (Figure 17C and D).
Interestingly, despite all mutants having reduced superantigenic activity, only SpeATRI
generated both consistent protection and high anti-SpeA IgG antibody titres. SpeAN20A
failed to both protect mice or generate an anti-SpeA antibody response. SpeAN20A/Y100A had
~50% protection rate and a variable anti-SpeA IgG profile. The mice that were protected
from infection by SpeAN20A/Y100A vaccination were shown to have a higher anti-SpeA IgG
titre, whereas mice with higher bacterial load had low anti-SpeA antibody titres. These data
suggest that when this SpeAN20A/Y100A vaccination does yield high anti-SpeA antibody
titres, the mice are protected (Appendix 3). Vaccination with SpeATETRA, which contains
all of the mutations of SpeATRI in addition to N20A, trended to produce enhanced, but not
significantly higher anti-SpeA IgG antibody titres (Figure 17C) with inconsistent
protection (5/8) (Figure 17B). In conclusion, the most successful toxoid that consistently
generated high anti-SAg antibody titres was SpeATRI that had amino acid substitutions only
within the MHC II binding interface.
Depletion of CD4+ and CD8+ T cells reduce S. pyogenes burden
Our finding that vaccination with wild-type SpeA and SEB generated unresponsive T cell
subsets that ultimately led to protection in these mice led us to assess whether these cells
were required for infection establishment by S. pyogenes. To determine this, we sought to
deplete specific T cell subsets using a previously published depletion strategy [458]
(Figure 18A) and subsequently assess the impact on nasopharyngeal infection. To confirm
the depletion potential of these antibodies, transgenic HLA-DQ8 mice were administered
three doses of T cell-depleting antibody, or isotype control, and cervical lymph nodes were
subjected to flow cytometry to assess T cell subset abundance. Lymphocytes were gated
using forward and side scatter, and CD4+ and CD8+ T cell subsets were analyzed (Figure
18B). Compared to the isotype control, administration of T cell-depleting antibodies
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Figure 17. Further mutations within the MHC II binding interface of SpeA generates
high IgG antibody titres and is protective.
A. Activation assay measuring ability of wild-type or toxoid SAgs to stimulate HLADR4/DQ8 murine splenocytes as determined by IL-2 production. Data represented as the
mean ± SEM of triplicate values from a single mouse. B. HLA-DR4/DQ8 mice were
vaccinated with a saline control or the indicated SpeA toxoid as previously described. Mice
were intranasally infected with 108 CFU of S. pyogenes MGAS8232 and sacrificed 48
hours later. Data points represent CFU from the cNT of individual mice. Horizontal bars
represent the mean. Horizontal dotted line indicates the theoretical limit of detection. C.
Serum was collected 24 hours prior to infection and used to assess IgG antibody titres using
ELISA (n ≥ 3). Data is represented as the mean ± SEM. Significance determined by oneway ANOVA with Dunnett’s post-hoc test (*, P < 0.05; **, P < 0.01). SpeA IL-2 activation
assay (Figure 15), cNT and IgG (Figure 11; designated 1 µg therein) are repeated values;
IL-2 activation assay, cNT and Ig data for control, SpeAY100A and SpeAHEXA data are
repeated from Figure 15.
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Figure 18. Depletion of CD4+ and CD8+ T cells reduces S. pyogenes nasopharyngeal
bacterial load.
A. T cell depletion protocol. B and C. Flow cytometric analysis of cervical lymph node
populations at day 0 post T cell depletion (n = 3 per group). B. Representative flow plots
for each treatment group stained for CD4 (APC-efluor 780) and CD8 (PE). Each sample
had the lymphocytes first gated upon using FSC and SSC. C. Percentage of CD4+ and
CD8+ cells to total lymphocyte population in both treatment groups. Data are shown as
mean ± SEM. Significance determined by Student’s t test (***, P < 0.001). D. Nasal
challenge of transgenic mice expressing HLA-DQ8 with 108 CFU S. pyogenes MGAS8232
post-injection with indicated treatments. Data points represent CFU from the complete
nasal turbinates (cNT) of individual mice 48 hours post-infection. Horizontal bars represent
the mean. The horizontal dotted line indicates limit of detection. Significance determined
by one-way ANOVA with Dunnett’s multiple comparisons post-hoc test (*, P < 0.05; **,
P < 0.01).
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significantly reduced the CD4+ and CD8+ subsets (Figure 18C). Next, mice were again
administered T cell-depleting antibodies as described above, but were infected with S.
pyogenes MGAS8232 for 48 hours. Mice were then sacrificed and cNT bacterial load was
assessed. Depletion of CD8+ alone, but not CD4+ T cells significantly reduced S. pyogenes
nasopharyngeal bacterial load; however, the greatest reduction was observed upon
depletion of both subsets (Figure 18D). These results support the requirement for CD4+
and CD8+ T cell subsets during S. pyogenes nasopharyngeal infection.
CD4+ and CD8+ T cell subset depletion has no impact on S. pneumoniae P1121
bacterial load
To determine whether the above-mentioned T cell depletion phenotype was specific to S.
pyogenes, another human-specific nasopharyngeal colonizer – Streptococcus pneumoniae
– was tested for its ability to infect T cell-depleted mice. We first assessed whether the
ability of S. pneumoniae to infect the nasopharynx of mice was human MHC II-dependent.
Both conventional C57Bl/6 and transgenic HLA-DR4/DQ8 mice were intranasally
infected with S. pneumoniae P1121 and bacterial load in the cNT was evaluated. It was
demonstrated that both strains of mice had high bacterial load 48 hours post-infection;
however, HLA-DR4/DQ8 mice did have a statistically higher bacterial yield (Figure 19A).
It was also shown that bacterial load was below the detectable limit in all but one lung
sample (Figure 19B) and in the blood (Figure 19C). The cNT bacterial burden was also
comparable to those seen in S. pyogenes infected HLA-DQ8 transgenic mice (Figure 8A).
Next, the impact of T cell depletion was measured. HLA-DQ8 mice were treated with T
cell depleting or isotype control antibodies as above, and mice were infected intranasally
with S. pneumoniae P1121. T cell depletion had no impact on infection (Figure 20A). To
ensure that the inoculation dose did not result in pneumonia or bacteremia, lung and blood
samples were plated for bacterial enumeration. It was determined that only one T cell
depleted mouse had bacteria above the detectable limit in the lungs but this was not
significantly different compared with control mice (Figure 20B). There were no bacteria
in the blood above the detectable limit (Figure 20C). This data supports the notion that the
conventional T cell subset dependence phenotypes observed in S. pyogenes MGAS8232
are not common to all human upper respiratory tract-infecting organisms.
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Figure 19. C57Bl/6 and HLA-DR4/DQ8 nasopharyngeal infection by S. pneumoniae.
Conventional C57Bl/6 or HLA-DR4/DQ8 mice were intranasally infected with 107 CFU
of S. pneumoniae P1121 for 48 hours. Mice were then sacrificed and cNT (A), lung (B)
and blood (C) were extracted, processed and plated for bacterial enumeration. Data points
represent CFU from indicated tissue of individual mice 48 hours post-infection. Horizontal
bars represent the mean. The horizontal dotted line indicates limit of detection.
Significance was determined by Student’s t test (*, P < 0.05).
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Figure 20. Depletion of conventional T cells has no impact on S. pneumoniae
nasopharyngeal infection.
HLA-DR4/DQ8 mice were treated with isotype control (black) or α-CD4 (GK1.5) and αCD8 (YTS 169.4) depleting antibodies (pink) and intranasally infected with 107 CFU S.
pneumoniae P1121. Mice were sacrificed 48 hours later and cNT (A), lung (B) and blood
(C) were isolated, processed, and plated for bacterial enumeration. Data points represent
CFU from indicated tissue of individual mice 48 hours post-infection. Horizontal bars
represent the mean. The horizontal dotted line indicates the theoretical limit of detection.
Statistical analysis was completed using Student’s t test.
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Responsive T cells are required for robust cytokine response during S. pyogenes
nasopharyngeal infection
To

assess

the

cytokine

and

chemokine

environment

during

SAg-rendered

unresponsiveness and T cell depletion followed by infection, supernatants from the cNT of
treated and infected mice were analyzed by multiplex cytokine array to test for the presence
of 32 cytokines. Statistical analyses were completed on individual cytokines within
treatment and infection groups. Any cytokine that showed a significant difference within
any of the treatment groups was included in the heat map for all groups. To compare the
cytokines between groups, the heat map displays individual cytokine concentrations
between all treatment groups which were normalized so that the highest concentration was
100% (Figure 21). Quantitative data is shown in Appendix 4. For S. pyogenes infections,
the most robust cytokine response can be seen in the sham-vaccinated (saline plus alum
adjuvant) or the isotype control (LTF-2) treated mice and includes: Th1-type cytokines
(TNFα, IL-1β and IL-12 [p70]); Th2-type cytokines (IL-4); Th17-type cytokines (IL-6 and
IL-17); chemokines (KC, IP-10, MCP-1, MIP-1α, MIP-1β, MIP-2 and LIF); and growth
factors (G-CSF and M-CSF) (Figure 21B and C; Appendix 4). Conversely, mice with T
cell subsets that were unresponsive to SpeA, either by wild-type SpeA or wild-type SEB
vaccination, or treatment with CD4 (GK1.5) and CD8 (YTS 169.4) T cell-depleting
antibodies (Figure 21B and C) had cytokine profiles similar to uninfected mice (Figure
21A). These results are in stark contrast to mice treated with isotype control or CD4 and
CD8 T cell-depleting antibodies and infected with S. pneumoniae (Figure 21D). T cell
depleted mice infected with S. pneumoniae demonstrated higher cytokine/chemokine
responses compared to isotype control treated mice. These elevated molecules included:
Th1-type cytokines (TNFα, IL-1α and IL-12 [p70]); Th2-type cytokines (IL-4); Th17-type
cytokines (IL-6 and IL-17); and chemokines (KC, IP-10, MCP-1, MIG and LIF) (Figure
21D). There were also numerous cytokines that were either not different between any
groups or did not conform to any obvious trends (Appendix 4). These results suggest that
the presence of responsive T cells plays an important role in modulating the
nasopharyngeal cytokine environment during S. pyogenes infections, which differs greatly
from that during infection with S. pneumoniae.
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Figure 21. Impact of superantigen-vaccination and T cell depletion on the murine
nasopharyngeal cytokine microenvironment following infection by S. pyogenes
MGAS8232.
HLA-expressing mice were either uninfected (A), vaccinated (B) or underwent T cell
depleting antibody treatment (C and D) prior to infection with either 108 CFU of S.
pyogenes MGAS8232 (B and C) or 107 S. pneumoniae P1121 (D) for 48 hours. Mice were
sacrificed and supernatant from cNT homogenates were procured for cytokine and
chemokine analysis. Data shown represents the mean cNT cytokine response that displayed
significant differences within any group. Values for each individual cytokine were
normalized to have the highest cytokine value as 100% (n ≥ 3 mice per group).
Corresponding quantitative data and statistical analyses are shown in Appendix 4.
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Chapter 4: Discussion
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Discussion
The primary barrier to preventing the greater than 500,000 deaths cause by GAS each year
[4] is the lack of a safe and effective vaccine. Although this topic has been extensively
studied for decades, there are numerous deterrents which have prevented this crucial
prophylactic from being developed, including the lack of monetary incentive (due to this
organism being a primary burden on developing, low income nations) and the potential for
developing a cross-reactive immune response upon immunization with bacterial
components leading to autoimmune sequelae [433,465]. The most promising vaccine
candidate thus far is a multivalent M protein-based vaccine that targets 26 of the most
common pharyngitis, invasive and rheumatogenic serotypes, and this vaccine has now
undergone phase I and II clinical trials [419] and a reformatted 30-valent vaccine has
undergone phase I trials [418,433]. The choice to target the M protein as a potential vaccine
component stems from experiments completed over 50 years ago in pioneering studies by
Rebecca Lancefield who demonstrated type-specific protective immunity in mice and
subsequently showed that in humans, bactericidal M protein antibodies persisted for years
after GAS infection [412]. Despite these findings, an overarching concern with M proteinbased vaccines is that there are over 200 known streptococcal emm-types with varying
distributions worldwide [49], presenting a possible complication of vaccine coverage and
the likelihood of selecting for emm-types not present in the vaccine. Recent findings have
shown that the 30-valent vaccine would protect against the majority of invasive- and
pharyngitis-associated emm-types in North America and Europe [14,58,421,422] and does
produce cross-reactive antibodies that target other emm-types [423,424]. This furthers the
potential of M protein-based vaccines, but it is considered unlikely that a universally
protective vaccine will ever arise from just targeting the M protein. Our belief is that a
vaccine that targets multiple bacterial components that are known to be crucial to the
establishment and/or maintenance of infection and survival of the organism in vivo would
be a more successful candidate.
Streptococcal infection of the throat, skin and/or mucosa often precedes autoimmune
sequelae [12,29,466], which results in the largest burden of GAS-associated disease
[4,467]. Therefore, prevention of bacterial colonization and infection would largely prevent

119

this disease burden. Previous findings from our laboratory that GAS SAgs are required for
efficient acute nasopharyngeal infection [377], and our demonstration herein that SAgs are
expressed during infection establishment (Figure 9) led us to consider these toxins as
potential vaccine candidates. One major benefit to the use of SAgs as vaccine candidates
is that there are only 11 known Group A streptococcal SAgs [187]. This makes the
generation of a pan-SAg vaccine more feasible compared to targeting the greater than 200
streptococcal emm-types. There is also data showing that administration of IVIG, which
contain SAg-neutralizing antibodies [468], may reduce patient mortality in some settings
[22,469,470], providing support for anti-SAg antibody-mediated protection against S.
pyogenes in humans. Although it has been noted that numerous SAgs have multiple alleles,
these generally differ in just a few amino acids [245], and thus it is probable that antibodies
generated against one allele would cross-react. The one documented exception to this is
SmeZ, in which there are over 50 variants [187]. Current analysis indicated that all tested
variants still target human TCR Vβ8+ cells, and those that do not are truncated and inactive
[205], which indicates that if antibodies towards the TCR-targeting interface of SmeZ
could be generated, this would likely neutralize most, if not all, active SmeZ variants.
Our vaccine analysis focused on SpeA, the only critical SAg in our human transgenic
mouse model of S. pyogenes MGAS8232 upper respiratory tract infection [377]. A goal of
this project was thus to produce a SpeA-based vaccine that generated antibody-mediated
protection in our nasopharyngeal infection model. Previous studies have used SpeA toxoids
as vaccine candidates [437,439] in severe and invasive disease, but not in the context of
nasopharyngeal infection or other non-invasive models. Our passive immunization
experiments show conclusively that anti-SpeA antibodies can be protective in S. pyogenes
nasopharyngeal infection (Figure 10). Although treatment with wild-type SpeA was
protective (Figure 13C), this was not antibody-mediated (Figure 13D), and instead was
due to rendering TCR Vβ8+ T cells unresponsive (Figure 14). Although protective in our
animal model, vaccinating with wild-type SAgs would never be plausible for human use.
This would primarily be due to the fact that SAgs are potent toxins that are capable of
causing severe diseases – such as TSS – at extremely low concentrations and could also
potentially drive an autoimmune response. Also, protection stemmed from rendering T cell
subsets unresponsive, and thus individuals receiving a wild-type SAg vaccination may
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invoke some level of protection against S. pyogenes infection, but may also be more
susceptible to infections normally controlled by functioning T cells, such as viral infection.
Nevertheless, this finding led us to pursue testing of attenuated SpeA toxoids in our
vaccination model. Previously described mutants SpeAY100A [454] and SpeAHEXA [437]
that were tested in this vaccination model did not satisfy the above mentioned criteria due
to protection stemming partially from unresponsive T cells (Figure 15B and 16) or
consistent, yet non-protective anti-SpeA antibody titres (Figure 15B and C), respectively.
These findings led us to further analyze SpeA TCR and MHC class II binding site mutants,
whereby we determined a further attenuated MHC II binding site mutant, SpeATRI, was
able to generate consistently high anti-SpeA antibody titres and consistent protection
(Figure 17B and C).
Mutation of asparagine at position 20 impacts the SpeA-TCR Vβ interacting interface
(Figure 5C). Interestingly, incorporation of this amino acid substitution alone or in tandem
with other substitutions generated a SpeA toxoid that failed to generate consistent
protection in our S. pyogenes nasopharyngeal infection model (Figure 17B). Furthermore,
SpeAN20A was incapable of activating murine T cells at all concentrations tested (Figure
17A) and did not induce anti-SpeA IgG antibodies (Figure 17C). SAgs have been
recognized for their ability to suppress antibody production [254,471]; however, this was
previously reported to be primarily through T cell-mediated perforin- and Fas-FasLdependent B cell apoptosis [472–474]. Since SpeAN20A no longer has T cell activating
potential (Figure 17A), this suggests an alternative, T cell-independent mechanism for
antibody suppression, possibly mediated through direct MHC II binding. This is further
supported by SpeATRI, which has only amino substitutions at the MHC II binding interface
and produces a robust and protective antibody response (Figure 17B and C). Vaccination
with toxoids containing mutations at both TCR and MHC II interacting interfaces
(SpeATETRA and SpeAHEXA) resulted in a similar bimodal protection phenotype (Figure
17B). The exact reasons for this phenotype have not yet been elucidated, but it is possible
that these amino acid substitutions removed a key epitope located within the TCR binding
site which prevented generation of SpeA-neutralizing antibodies. Alternatively, TCR
binding site mutant SAgs may not be appropriately trafficked to B cell germinal centers
which would prevent a robust Ab response. Further experimentation will be required to
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elucidate the mechanism of T cell-independent antibody suppression, as well as the lack of
protection from antibodies that can bind the wild-type toxin. However, our discovery of
SpeATRI and its effectiveness as a vaccine against GAS further support toxoid SAgs as
potential vaccine candidates to be used in a multi-component vaccine.
The mammalian adaptive immune system is known to be a critical component for
protecting the host against infection. More specifically, T lymphocytes are known to be
crucial components, aiding in the removal of viruses and intracellular pathogens, as well
as modulating of immune microenvironments and stimulating antibody production by B
cells. Through extremely diverse TCRs, T cells can recognize an astonishing number of
peptides when presented on MHC molecules. It is thus not surprising that T cells are
beneficial to the host in numerous infection models including those involving
Mycobacterium tuberculosis [475], Haemophilus influenza [476], Salmonella enterica
serovar Typhimurium [477] and Listeria monocytogenes [458]. Interestingly, in the case
of S. pyogenes, a robust nasopharyngeal infection required the presence of SAg-responsive
T cells. Vaccination with wild-type SpeA and SEB unexpectedly protected mice from S.
pyogenes nasopharyngeal infection without the generation of anti-SAg antibodies (Figure
13C and D). We were able to show that this protection was due to rendering specific SAgtargeted Vβ T cells unresponsive (Figure 14). Depleting CD4+ and CD8+ T cells via
antibody administration was also shown to be detrimental to GAS infection of the upper
respiratory tract (Figure 18). Interestingly, removal of CD8+ T cells alone impaired
nasopharyngeal infection (Figure 18D); however, SAgs are able to activate both CD4+ and
CD8+ T cells (Figure 6C), and thus we suspect that although both cells likely contribute
to this phenotype, CD8+ T cells may be more numerically dominant within this
environment (Figure 18C). Since we were able to detect activation of SpeA-targeted Vβ8+
T cells in vivo during S. pyogenes nasopharyngeal infection (Figure 9), and previous work
from our laboratory indicates that both host expression of human MHC II (HLA-DQ8) and
expression of SpeA are critical for S. pyogenes infection [377], this work supports that S.
pyogenes requires Vβ-specific and functional T cells to promote upper respiratory tract
infection.

122

This S. pyogenes T cell-dependent infection phenotype was shown to be in contrast to
infection with S. pneumoniae, another Gram-positive, human nasopharyngeal colonizer
that can disseminate from this site to cause a wide variety of invasive diseases
[451,452,460]. Importantly, S. pneumoniae does not produce any known SAgs and thus its
ability to colonize and infect the upper respiratory tract is completely independent of these
toxins. S. pneumoniae was shown to infect HLA-DQ8 transgenic mice better than C57Bl/6
mice (Figure 19A), however, both infection groups harbored ~5 logs of bacteria or more,
on average, and thus it appears that the role MHC II plays in this infection model is minimal
and not as pronounced as with S. pyogenes (Figure 8). Active immunity against S.
pneumoniae nasopharyngeal infection has been shown to be mediated by CD4+ T cells
[478], however, depletion of this T cell subset did not impact bacterial load at 48 hours
(Figure 20A). This result was not unexpected, as mice were naïve to S. pneumoniae
infection and the infection timeframe was too short to mount an adaptive immune response.
These results demonstrate that although both organisms colonize a similar niche, their
mechanisms for doing so appear to be very different.
Inflammation is a hallmark of the host response to an invading pathogen and generally acts
to recruit factors that promote the clearance of the assaulting organism. In the presence of
functioning T cells, when S. pyogenes had high bacterial load (Figure 13C and 18D), a
robust cytokine and chemokine response was observed in the nasopharyngeal environment
(Figure 21B, C and Appendix 4). Conversely, when bacterial load in the murine cNT was
decreased by SpeA or SEB vaccination (Figure 13C) or CD4+ and CD8+ T cell depletion
(Figure 18D), the cytokine and chemokine profile mimicked that of uninfected mice
(Figure 21A, B, C and Appendix 4). There was no significant impact on S. pneumoniae
bacterial load upon CD4+ and CD8+ T cell depletion; however, a trend of increased CFUs
was observed in T cell depleted mice (Figure 20A), accompanied by an enhanced cytokine
response (Figure 21D). These results indicated that there is a consistent inflammatory
signature when bacterial load is high. If an organism is able to avoid mucocilliary clearance
mechanisms, its next goal is to adhere to the underlying epithelial surface [479]. This
binding would theoretically also engage pattern recognition receptors of the innate immune
system resulting in inflammation [480]. Since inflammatory cytokine levels were
comparable in wild-type SAg vaccinated (SpeA and SEB), T cell-depleted (CD4 and CD8
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together), as well as uninfected mice, this would indicate that in the absence of SAg-driven
T cell activation, S. pyogenes cannot initiate even the earliest steps of nasopharyngeal
colonization. Taken further, it can be hypothesized that this early inflammatory response
is favorable for the bacteria and could provide a suitable environment for it to flourish.
There are other examples of bacteria-generated inflammation that appear to aid in the
establishment of infection. Neisseria gonorrhoeae has been shown to secrete the modified
sugar heptose-1,7-bisphosphate (HBP) as a novel pathogen-associated molecular pattern
(PAMP) that is recognized by innate immune receptors in host cells, leading to an
inflammatory response [481–483]. All analyzed Gram-negative organisms can produce
HBP, but Neisseria species were found to release this sugar during growth [481],
implicating an ‘intent’ by the organism to cause this immune response. It is currently
unknown as to why this organism in particular liberates this molecule, but it does have
interesting implications in pathogen-intended inflammation. Lupp et al. were also able to
show that inflammation in a murine model of infectious colitis benefitted the infecting
bacteria by eliminating the endogenous microflora and supporting the growth of introduced
aerobic bacteria [484]. In a model of murine chronic otitis media, nontypeable
Haemophilus influenzae was found to persist for up to two months in a cytokine rich
environment of IL-1β, TNF-α, IL-10 and transforming growth factor (TGF)-β. Upon
removal of T regulatory (Treg) cells, a ~3 log reduction of bacteria was demonstrated [485].
Although SAgs can induce Treg cells [486,487], our data does not suggest a Treg-dependent
phenotype as IL-10 was uniformly very low (<10 pg/mL) (Appendix 4) in all experimental
conditions, and infection with S. pyogenes induced a prominent IL-6 and IL-17 response
(Figure 21; Appendix 4). Therefore, our data suggests a more redundant role for CD4+
and CD8+ T cells. Both S. pyogenes and H. influenzae are regularly found in cases of human
recurrent acute tonsillitis and tonsillar hypertrophy [488] and these patients are known to
have an increase in IL-1α, IL-1β and TNF-α secreting cells in their tonsillar tissue [489].
Tonsillar cells from these patients re-stimulated with heat killed H. influenzae or S.
pyogenes similarly had an increase in these, and other, Th1 cytokines [490]. These
cytokines were also observed when the S. pyogenes bacterial load was high in the cNT of
infected mice (control vaccinated and isotype control treated mice; Figure 21B and C). All
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of these data suggest that certain organisms many induce an inflammatory environment
upon infection to assist the microbe in the early stages of infection.
A major question that has yet to be answered is what biological role do SAgs play in the
life cycle of S. pyogenes. SAgs have been primarily associated with severe and invasive
diseases [187], however, the high conservation and apparent functional redundancy of
these toxins indicate that they may play a more important role in S. pyogenes biology. Our
findings support the hypothesis that SAgs are critical factors at the early stage of
nasopharyngeal infection. Upon introduction into the upper respiratory tract, GAS
upregulates numerous virulence and colonization factors, including SAgs. This has been
well documented in vivo during the early colonization phase in a non-human primate model
of GAS pharyngitis [327]. Secreted SAgs would likely interact with T cells and APCs in
the local lymph node environments such as the Waldeyer’s ring in humans or the NALT in
the murine nasopharynx. This would stimulate a local inflammatory response driven by T
lymphocyte activation, which may perform a number of crucial tasks for the bacterium
including: suppression of innate phagocytic cell recruitment or function; expose important
binding receptors on host cells; enhance nutrient acquisition by the pathogen; and/or inhibit
members of the endogenous microbiota to reduce competition (Figure 22). Interestingly,
previously published work from our laboratory has indicated a different role for SAg toxins
during S. aureus nasopharyngeal infection. S. aureus SAg knockout strains were shown to
have higher bacterial densities in the nasal cavity compared to wild-type counterparts,
indicating a role for SAgs in regulating bacterial densities during colonization [491]. The
specific benefits gained by both S. pyogenes and S. aureus manipulation of the local
immune environment by producing SAgs remains incompletely understood, but future
research will further elucidate the mechanistic role(s) that these toxins play in both
organisms biology.
This thesis provides valuable insight into the host-pathogen interaction of S. pyogenes,
however, there are limitations to this study. First and foremost, GAS is a human-specific
pathogen, and although our model does well represent nasopharyngeal infection, it is still
not completely analogous to a human infection. Future studies should assess antibodymediated protection and T cell dependence in a more longitudinal model representing
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colonization (vaginal colonization [389]) and/or a more human-like model (non-human
primate [403]). Another limitation was that we were only able to test one strain of S.
pyogenes. Future studies should analyze other isolates, such as the endemic emm1 strain
(MGAS5005 [492] or 5448 [90,493]). Vaccine analysis focused primarily on the SAg
SpeA. It will be important to assess other streptococcal SAgs and confirm that mutations
to the MHC interacting interface will confer a similar protective phenotype upon
vaccination. Lastly, many of the experiments herein used a minimal number of animals to
reach statistical significance. Although this was due to limitations in murine colony
breeding, it was noted that future work should run statistical power tests to determine the
appropriate number of animals to use in each experiment and do everything possible to
reach that number of samples per group.
To conclude, within this work, we were able to detect expression of the SAg SpeA in vivo
during S. pyogenes nasopharyngeal infection, further implicating the role of these toxins at
this critical juncture of host-pathogen interaction. Numerous SpeA toxoid variants were
also designed and generated to assess their ability to generate protective SAg-specific
antibodies in vivo. Antibody-mediated protection was successfully demonstrated against S.
pyogenes nasopharyngeal infection using both passive immunization and vaccination with
a SpeA MHC II binding interface variant, SpeATRI. Vaccination of mice with wild-type
SAgs and T cell depletion experiments were able to demonstrate that S. pyogenes requires
responsive Vβ-specific T cells in order to infect the cNT, a phenotype to our knowledge
that is completely unique to a bacterial pathogen. We were also able to show that in the
presence of T cells, S. pyogenes infection correlates with a robust cytokine response that
was completely absent when T cells are unresponsive or depleted. This implicates a T celldriven cytokine environment that is necessary for the establishment of infection. To our
knowledge, this thesis presents the first use of a toxoid SAg to generate antibody-mediated
protection against S. pyogenes nasopharyngeal infection. From this work, there is now a
template to generate other SAg toxoids that can be used to create a potential vaccine
containing all streptococcal SAgs, which offers a different approach to current vaccine
strategies against S. pyogenes. Additionally, this work helps to guide the future of SAg
research, from a toxin that causes severe disease to a tool used by bacteria to establish
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Figure 22. Proposed mechanism of superantigen benefit to S. pyogenes.
S. pyogenes (group A streptococcus; GAS) gains access to the nasopharynx of its host and
quickly up-regulates virulence factors including SAgs (1). SAgs traverse the epithelium to
the local lymph environment such as Waldery’s ring in humans or the NALT in mice (2).
In the local lymph environment SAgs are able to activate both T cells (T) and antigen
presenting cells (APC) via interacting with the TCR and MHC II, respectively, which leads
to cytokine and chemokine production from both cell subset (3). Numerous bacterial
benefits are possible from cytokine and chemokine production including: suppression of
innate immune cell recruitment/function; exposure of binding receptors; enhanced nutrient
acquisition; and removal of endogenous competing microflora (4). These outcomes would
then allow the bacteria to survive and prosper in the nasopharynx.
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infection. Analyzing SAgs from this perspective may have wide-reaching implications on
the numerous organisms and viruses that utilize these truly unique proteins.
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Appendix 2. Animal ethics approval certification.
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Appendix 3. Vaccination with SpeAN20A/Y100A elicits an antibody-dependent bimodal
phenotype.
A. HLA-DR4/DQ8 mice were vaccinated with SpeAN20A/Y100A and intranasally infected
with 108 CFU of S. pyogenes MGAS8232. Data points represent CFU from the cNT of
individual mice 48 hours post infection. Horizontal bars represent the mean. Horizontal
dotted line indicates limit of detection. B. Serum was collected 24 hours prior to infection
and used to assess IgG antibody titres using ELISA (n ≥ 3). Data represented as the mean
± SEM. Significance determined by Student’s t test (***, P < 0.001). The cNT bacterial
load and anti-SpeA IgG titre data have already been reported (Figure 17B and C,
respectively).
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Appendix 4. Cytokine response from complete nasal turbinates during streptococcal
infection after indicated treatment.
Mice were treated with T cell depleting antibodies (CD4 [GK1.5], CD8 [YTS 169.4] or
combination), an isotype control (LTF-2) or wild-type SAg vaccination (SpeA or SEB) or
control (sham) and infected intranasally with either 108 CFU S. pyogenes MGAS8232 or
107 S. pneumoniae P1121. Sacrifice occurred 48 hours later and complete nasal turbinates
(cNT) homogenates were analyzed for multiple cytokines and chemokines (Th1-type [A];
Th2-type cytokines [B]; Treg cytokines [C]; Th17 cytokines [D]; chemokines [E]; or
growth factors [F]). Data represents the mean ± SEM of cNT cytokine/chemokine
concentration (pg mL-1) (n ≥ 3 mice per group). Significance was determined by one-way
ANOVA with Dunnett’s multiple comparison post-hoc test (S. pyogenes) or Student’s t test
(S. pneumoniae) (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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